TransCode Therapeutics Q3 loss widens to $107M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
TransCode Therapeutics, Inc. (RNAZ) reported a third-quarter net loss of $107,382,178, versus $4,856,051 a year earlier; the nine-month net loss was $131,917,377, compared with $21,217,966. The quarter included a $102,000,000 noncash impairment of the Seviprotimut-L in-process research and development asset, written down to $12,300,000. Cash was $4,635,839 at September 30, 2026, versus $17,813,521 at December 31, 2025; operating activities used $18,042,782 in cash over nine months.
The company cited recurring and expected losses and substantial doubt about continuing as a going concern without additional capital, although management believes September 30 cash can fund operations into approximately the first quarter of 2027. A $840,975 cash prepayment was made on the Yorkville notes in September; a November 2026 amortization event requires monthly cash payments unless waived, and discussions with Yorkville continue. The board initiated a strategic process in October with no assurance it will result in a transaction. TTX-MC138 Phase 2a enrollment is expected in the first half of 2027, following delays tied to a collaboration and refocused recruitment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Major point$102,000,000 impairment reduced Seviprotimut-L IPR&D to $12,300,000. 4.6× market cap
- Major pointAt September 30, $4,635,839 cash; substantial going-concern doubt without additional capital.
- Moderate point. Forward-looking: it has not happened yet and may not happen.November 2026 amortization event requires monthly cash payments unless waived.
- Minor point$107,382,178 quarterly net loss versus $4,856,051 in 2025.
- Minor point$131,917,377 nine-month net loss versus $21,217,966 in 2025.
- Minor point$18,042,782 operating cash use versus $11,374,219 in 2025.
Filing Explained
A separate Yorkville agreement leaves up to fourteen million dollars of stock sales at the company’s option, not a committed issuance.
By
Issuing additional shares increases the total share count and reduces existing holders’ percentage ownership absent offsetting changes; this completed conversion therefore reduced existing common holders’ percentage stakes.
Separately, the SEPA allows TransCode to sell up to
If the company directs an advance under the SEPA, the purchase price is 97% of the lowest daily VWAP during the three consecutive trading days beginning when the company delivers an advance notice.
Key Figures
Key Terms
in-process research and development financial
going concern financial
Standby Equity Purchase Agreement financial
Amortization Event financial
Floor Price financial
Level 3 measurement financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What drove TransCode Therapeutics (RNAZ)'s third-quarter net loss?
How much cash did RNAZ have at September 30, 2026?
What are RNAZ's Yorkville note payment terms after the November amortization event?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO ___________ |
Commission File Number:
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |
, Massachusetts | |
(Address of Principal Executive Offices) | (Zip Code) |
(
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
| | |||
Title of Each Class | | Trading Symbol(s) | | Name of Each Exchange on Which Registered |
| |
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☒ | Smaller reporting company | ||
| | Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES
1
The number of shares of Registrant’s Common Stock outstanding as of November 12, 2026, was
Table of Contents
TRANSCODE THERAPEUTICS, INC.
QUARTERLY REPORT ON FORM 10-Q
Table of Contents
| ||
| | PAGE |
| | |
PART I. FINANCIAL INFORMATION | | |
| | |
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | | 4 |
CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2026 (UNAUDITED) AND DECEMBER 31, 2025 | | 4 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (UNAUDITED) | | 5 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN NON-VOTING CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (UNAUDITED) | | 6 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (UNAUDITED) | | 7 |
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) | | 8 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | | 24 |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | | 45 |
ITEM 4. CONTROLS AND PROCEDURES | | 46 |
| | |
PART II. OTHER INFORMATION | | |
| | |
ITEM 1. LEGAL PROCEEDINGS | | 48 |
ITEM 1A. RISK FACTORS | | 48 |
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | | 51 |
ITEM 3. DEFAULTS UPON SENIOR SECURITIES | | 52 |
ITEM 4. MINE SAFETY DISCLOSURES | | 52 |
ITEM 5. OTHER INFORMATION | | 52 |
ITEM 6. EXHIBITS | | 52 |
SIGNATURE | | 54 |
1
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”). We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” “will,” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:
| Ø | our cash position, our estimates and expectations regarding our capital requirements, cash and expense levels, liquidity sources, our need for additional financing and our ability to obtain, on satisfactory terms or at all, the financing required to support operations, research, development, clinical trials, and commercialization of products; |
| Ø | our Board’s strategic process to evaluate opportunities designed to maximize the value of our Company and our oncology portfolio, including our lead product candidate, TTX-MC138; |
| Ø | potential delisting of our common stock from trading on the Nasdaq Capital Market; |
| Ø | our ability to continue as a going concern; |
| Ø | the results and timing of our preclinical and clinical trial activities, including but not limited to our ability to enroll timely a sufficient number of patients to advance our clinical trials; |
| Ø | our ability to expand our therapeutic candidate portfolio through internal research and development or the acquisition or in-licensing of intellectual property assets; |
| Ø | the therapeutic benefits, effectiveness and safety of our therapeutic candidates; |
| Ø | our ability to receive regulatory approval for our therapeutic candidates in the United States, Europe and other geographies; |
| Ø | the expected regulatory approval pathway for our therapeutic candidates; |
| Ø | potential changes in regulatory requirements, and delays or negative outcomes from the regulatory approval process; |
| Ø | our ability to maintain adequate quality processes and oversight of vendors; |
| Ø | our ability to secure raw materials to support continued drug substance and drug product manufacturing; |
| Ø | our reliance on third-parties for the planning, conduct, management and monitoring of clinical trials, for the manufacture of clinical drug supplies and drug product meeting our specifications, and for other requirements; |
| Ø | our estimates of the size and characteristics of the markets that may be addressed by our therapeutic candidates; |
| Ø | market acceptance of our therapeutic candidates if approved for marketing in the United States or other countries; |
| Ø | our ability to successfully commercialize our therapeutic candidates, if approved for marketing; |
| Ø | the safety and efficacy of therapeutics marketed by our competitors that are targeted to indications which our therapeutic candidates have been developed to treat; |
| Ø | our ability to utilize our proprietary technological approach to develop and commercialize our therapeutic candidates; |
| Ø | our heavy dependence on licensed intellectual property, including our ability to source and maintain licenses from third-party owners; |
| Ø | our ability to protect our own or in-licensed intellectual property and operate our business without infringing the intellectual property rights of others; |
| Ø | our ability to attract, retain and motivate key personnel; |
| Ø | our ability to generate revenue and become profitable; |
2
Table of Contents
| Ø | the outcome of our Phase Ia clinical trial with TTX-MC138, which commenced in the third quarter of 2024 and in which there are patients continuing on that trial, and our Phase IIa clinical trial, which we have recently initiated, and our ability to complete this trial; |
| Ø | the impact of natural disasters, global pandemics, armed conflicts and wars, labor disputes, lack of raw materials or other supplies, issues with facilities and equipment, or other forms of disruption to business operations at our manufacturing or laboratory facilities or those of our vendors; |
| Ø | potential collaborations to license and commercialize any therapeutic candidates for which we receive regulatory approval in the future in or outside the United States; and |
| Ø | other risks and uncertainties, including those listed under the caption “Risk Factors” in this Quarterly Report on Form 10-Q and in our other regulatory filings. |
The risks set forth above are not exhaustive. Other sections of this Quarterly Report on Form 10-Q may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all risk factors, nor can we assess the impact of all risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events and with respect to our business and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025 and under Part II, Item 1A, “Risk Factors,” and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You are advised, however, to consult any further disclosure we make in our reports filed with the U.S. Securities and Exchange Commission (the “SEC”).
This Quarterly Report on Form 10-Q may include data that we obtained from industry publications and third-party research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. This Quarterly Report on Form 10-Q also may include data based on our own internal estimates and research, including estimates regarding our consolidated financial statements and business operations. Our internal estimates have not been verified by any independent source and, while we believe any data obtained from industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Such third-party data, as well as our internal estimates and research, are subject to a high degree of uncertainty and risk due to a variety of factors, including those described in Part II, Item 1A, “Risk Factors,” and elsewhere in this Quarterly Report on Form 10-Q. These and other factors could cause our results to differ materially from those expressed in or suggested by this Quarterly Report on Form 10-Q.
This Quarterly Report on Form 10-Q may contain trademarks, service marks and trade names of third parties which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this Quarterly Report on Form 10-Q is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.
For purposes of this Quarterly Report on Form 10-Q, TransCode Therapeutics® is referred to as TransCode. Additionally, “we,” “our,” “us” and the “Company” refer to TransCode.
3
Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
TRANSCODE THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| | | | | | |
| | September 30, | | December 31, | ||
| | 2026 | | 2025 | ||
Assets | | (Unaudited) | | | | |
Current assets: | | | | | | |
Cash | | $ | | | $ | |
Grant receivable | | | — | | | |
Reimbursement right | | | — | | | |
Due from related party | | | | | | |
Prepaid expenses and other current assets | | | | | | |
Total current assets | | | | | | |
Property and equipment, net of depreciation | | | | | | |
Goodwill | | | | | | |
Intangible assets | | | | | | |
Total assets | | $ | | | $ | |
| | | | | | |
Liabilities, Non-Voting Convertible Preferred Stock, and Stockholders’ Equity | | | | | | |
Current liabilities: | | | | | | |
Accounts payable and accrued expenses | | $ | | | $ | |
Notes payable - convertible, at fair value | | | | | | — |
Total current liabilities | | | | | | |
Long-term liabilities: | | | | | | |
Warrant liability - Series C | | | | | | |
Contingent consideration | | | | | | |
Deferred tax liability | | | | | | |
Long-term liabilities | | | | | | |
Total liabilities | | | | | | |
Commitments and contingencies | | | | | | |
Series A Non-Voting Convertible Preferred Stock, $ | | | — | | | |
Series B Non-Voting Convertible Preferred Stock, $ | | | — | | | — |
Stockholders’ equity: | | | | | | |
Common stock – $ | | | | | | |
Additional paid-in capital | | | | | | |
Accumulated deficit | | | ( | | | ( |
Total stockholders’ equity | | | | | | |
Total liabilities, non-voting convertible preferred stock, and stockholders' equity | | $ | | | $ | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
Table of Contents
TRANSCODE THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, | | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | | ||||
Operating expenses | | | | | | | | | | | | | |
Research and development | | $ | | | $ | | | $ | | | $ | | |
Acquired in-process research and development expense | | | — | | | — | | | | | | — | |
General and administrative | | | | | | | | | | | | | |
SEPA financing issuance costs | | | | | | — | | | | | | — | |
Impairment of in-process research and development | | | | | | — | | | | | | — | |
Total operating expenses | | | | | | | | | | | | | |
Operating loss | | | ( | | | ( | | | ( | | | ( | |
| | | | | | | | | | | | | |
Other income (expense) | | | | | | | | | | | | | |
Change in fair value of warrant liabilities | | | | | | ( | | | | | | ( | |
Change in fair value of contingent consideration | | | | | | — | | | | | | — | |
Change in fair value of convertible notes payable | | | | | | — | | | | | | — | |
Grant income | | | | | | | | | | | | | |
Currency exchange loss | | | ( | | | ( | | | ( | | | ( | |
Interest income | | | | | | | | | | | | | |
Interest expense | | | ( | | | ( | | | ( | | | ( | |
Total other income (expense) | | | | | | ( | | | | | | ( | |
Loss before income tax provision | | | ( | | | ( | | | ( | | | ( | |
Deferred income tax provision | | | | | | — | | | | | | — | |
Net loss | | | ( | | | ( | | | ( | | | ( | |
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | | | — | | | | | | ( | | | — | |
Net loss attributable to common stockholders | | $ | ( | | $ | ( | | $ | ( | | $ | ( | |
| | | | | | | | | | | | | |
Basic and diluted net loss per share | | | | | | | | | | | | | |
Net loss attributable to common stockholders | | $ | ( | | $ | ( | | $ | ( | | $ | ( | |
Weighted-average common shares outstanding | | | | | | | | | | | | | |
Net loss per share | | $ | ( | | $ | ( | | $ | ( | | $ | ( | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
Table of Contents
TRANSCODE THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN NON-VOTING CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Series A Non-Voting | | Series B Non-Voting | | | Series B Non-Voting | | Series C Non-Voting | | | | | | | | | | | | | Total | |||||||||||||
| | Convertible | | Convertible | | | Convertible | | Convertible | | | | | | | Additional | | | | | Stockholders’ | ||||||||||||||
| | Preferred Stock | | Preferred Stock | | | Preferred Stock | | Preferred Stock | | Common Stock | | Paid-In | | Accumulated | | Equity | ||||||||||||||||||
| | Shares | | Amount | | Shares | | Amount | | | Shares | | Amount | | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | (Deficit) | ||||||||
Nine months ended September 30, 2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance, December 31, 2025 | | | | $ | | | — | | $ | — | | | | | $ | — | | — | | $ | — | | | | $ | | | $ | | | $ | ( | | $ | |
Net loss | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | — | | | ( | | | ( |
Issuance of Series C Preferred Stock, net of issuance costs | | — | | | — | | — | | | — | | | — | | | — | | | | | | | — | | | — | | | | | | — | | | |
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | | — | | | | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | ( | | | — | | | ( |
Balance, March 31, 2026 (unaudited) | | | | | | | — | | | — | | | | | | — | | | | | | | | | | | | | | | | ( | | | |
Net loss | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | — | | | ( | | | ( |
Reclassification of Series B Preferred Stock from Permanent Equity to Temporary Equity | | — | | | — | | | | | | | | ( | | | — | | — | | | — | | — | | | — | | | ( | | | — | | | ( |
Payment of SEPA commitment fee in common shares | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | | | | | | | | | | — | | | |
Conversion of convertible note into common stock | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | | | | | | | | | | — | | | |
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | | | | | | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | ( | | | — | | | ( |
Balance, June 30, 2026 (unaudited) | | | | | | | | | | | | | — | | | — | | | | | | | | | | | | | | | | ( | | | ( |
Net loss | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | — | | | ( | | | ( |
Conversion of preferred stock into common stock | | ( | | | ( | | ( | | | ( | | | — | | | — | | ( | | | ( | | | | | | | | | | | — | | | |
Conversion of convertible note into common stock | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | | | | | | | | | | — | | | |
Share-based compensation | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | | | | — | | | |
Balance, September 30, 2026 (unaudited) | | — | | $ | — | | — | | $ | — | | | — | | $ | — | | — | | $ | — | | | | $ | | | $ | | | $ | ( | | $ | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Nine months ended September 30, 2025 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance, December 31, 2024 | | — | | $ | — | | — | | $ | — | | | — | | $ | — | | — | | $ | — | | | | $ | | | $ | | | $ | ( | | $ | ( |
Net loss | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | — | | | ( | | | ( |
Issuances of common stock, net | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | | | | | | | | | | — | | | |
Exercise of Series D warrants | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | | | | — | | | |
Share-based compensation | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | | | | — | | | |
Balance, March 31, 2025 (unaudited) | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | | | | | | | | | | ( | | | |
Net loss | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | — | | | ( | | | ( |
Share-based compensation | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | | | | — | | | |
Balance, June 30, 2025 (unaudited) | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | | | | | | | | | | ( | | | |
Net loss | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | — | | | ( | | | ( |
Share based compensation | | — | | | — | | — | | | — | | | — | | | — | | — | | | — | | — | | | — | | | | | | — | | | |
Balance, September 30, 2025 (unaudited) | | — | | $ | — | | — | | $ | — | | | — | | $ | — | | — | | $ | — | | | | $ | | | $ | | | $ | ( | | $ | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
Table of Contents
TRANSCODE THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| | | | | | | |
| | Nine months ended | | ||||
| | September 30, | | ||||
| | 2026 | | 2025 | | ||
Cash flows from operating activities: | | | | | | | |
Net loss | | $ | ( | | $ | ( | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | |
Depreciation | | | | | | | |
Amortization of right-of-use asset | | | — | | | | |
Non-cash acquired in-process research and development cost | | | | | | — | |
Impairment of in-process research and development | | | | | | — | |
Non-cash SEPA commitment fee settled in common stock | | | | | | — | |
Share-based compensation expense | | | | | | | |
Loss on litigation settlement | | | | | | — | |
Change in fair value of contingent consideration | | | ( | | | — | |
Change in fair value of warrant liabilities | | | ( | | | | |
Change in fair value of convertible notes payable | | | ( | | | — | |
Accrued interest paid on settlement of convertible notes | | | ( | | | — | |
Deferred income tax provision | | | ( | | | — | |
Changes in assets and liabilities: | | | | | | | |
Prepaid expenses and other current assets | | | ( | | | ( | |
Accounts payable and accrued expenses | | | | | | | |
Deferred grant income | | | — | | | ( | |
Grant receivable | | | | | | ( | |
Reimbursement right asset | | | | | | — | |
Security deposit | | | — | | | | |
Operating lease liability | | | — | | | ( | |
Due from related parties | | | ( | | | — | |
Net cash used in operating activities | | | ( | | | ( | |
Cash flows from financing activities: | | | | | | | |
Net proceeds from sales of common stock | | | — | | | | |
Payments of deferred offering costs | | | — | | | ( | |
Proceeds from issuance of convertible promissory notes, net of purchase discount | | | | | | — | |
Repayment of convertible notes, including prepayment premium | | | ( | | | — | |
Net cash provided by financing activities | | | | | | | |
Net change in cash | | | ( | | | ( | |
Cash, beginning of period | | | | | | | |
Cash, end of period | | $ | | | $ | | |
| | | | | | | |
Supplemental disclosure of cash flow information | | | | | | | |
Cash paid during the period for: | | | | | | | |
Interest related to insurance premium payment plan | | $ | | | $ | | |
Supplemental disclosure of non-cash investing and financing activities: | | | | | | | |
Series C Preferred Stock issued for acquired in-process research and development | | $ | | | $ | — | |
Conversion of Series A and Series B Preferred Stock into common stock | | $ | | | $ | — | |
Settlement of SEPA commitment fee in common stock | | $ | | | $ | — | |
Conversion of convertible promissory notes (fair value) to common stock | | $ | | | $ | — | |
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | | $ | | | $ | — | |
Exercise of Series D warrants | | $ | — | | $ | | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
(1) Nature of Business and Liquidity
TransCode Therapeutics, Inc. (the “Company” or “TransCode”) was incorporated on January 11, 2016, under the laws of the State of Delaware. TransCode is a clinical-stage biopharmaceutical company focused primarily on the research and development (“R&D”) of innovative drugs for treating cancer. The Company operates in
On October 8, 2025, the Company acquired
The Company intends to continue developing TTX-MC138 and on developing Seviprotimut-L as available funding allows, with the primary near-term focus on advancing TTX-MC138 in a Phase 2a clinical trial for patients with CRC. The Company is evaluating the potential to augment Seviprotimut-L's anti-cancer effects by combining it with TTX-MC138 to address micrometastases in stage IIB and IIC melanoma patients.
Going Concern
These consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the continuation of operations, realization of assets and liquidation of liabilities in the ordinary course of business. Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
For the nine months ended September 30, 2026, consolidated net cash used in operating activities was approximately $
Management's plans to address the Company's liquidity needs include the formal strategic process initiated by the Board of Directors in October 2026 (see Note 18), additional equity or debt financing, including sales of Common Stock under the SEPA, and reductions in planned expenditures. There can be no assurance that these plans will be completed on acceptable terms, or at all, and if they are not, the Company may be required to delay or discontinue its development programs, restructure its liabilities or cease operations. No plan of liquidation has been approved, and these condensed consolidated financial statements have been prepared on a going concern basis.
8
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
(2) Summary of Significant Accounting Policies
(a) Basis of Presentation
The interim consolidated financial statements included herein are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, ABCJ, LLC, including ABCJ’s wholly-owned subsidiaries, Polynoma, LLC and Polynoma, Inc. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, these consolidated financial statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the consolidated financial position of the Company at September 30, 2026, its consolidated results of operations for the three and nine months ended September 30, 2026 and 2025, and its consolidated cash flows for the nine months ended September 30, 2026 and 2025. The interim consolidated results of operations are not necessarily indicative of consolidated results to be expected for a full year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2025, and notes thereto contained in the Company’s Annual Report on Form 10-K, filed with the SEC. The condensed consolidated balance sheet at December 31, 2025, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. There have been no material changes to the Company's significant accounting policies from those described in Note 2 to the audited consolidated financial statements included in the 2025 Annual Report on Form 10-K, except as described below. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.
(b) Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of consolidated revenues and expenses during the reporting period. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Significant items subject to such estimates and assumptions include, but are not limited to, accrued research and development costs, including work performed but not yet billed by contract manufacturers and clinical research organizations; the fair values of the Seviprotimut-L in-process research and development asset and of the Company's reporting unit used in testing those assets and goodwill for impairment; the fair value of the contingent consideration liability arising from the Acquisition; the assessment of whether a payment under the contingent value rights ("CVRs") issued in connection with the Acquisition is probable; the fair values of the Convertible Notes, the SEPA Option and the Series C Warrant liability; share-based compensation; the valuation allowance against deferred tax assets; and the recognition of grant income. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. These judgments can be subjective and complex. Accounting estimates used in the preparation of these consolidated financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates.
9
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
(c) | Goodwill and Indefinite-Lived Intangible Assets |
Goodwill and acquired in-process research and development ("IPR&D") are not amortized. They are tested for impairment annually on October 1 and between annual tests when events or changes in circumstances indicate that it is more likely than not that the IPR&D asset is impaired or that the fair value of the Company's single reporting unit is less than its carrying amount. During the three months ended September 30, 2026, the sustained decline in the Company's stock price and market capitalization, together with the Company's limited available funding to advance Seviprotimut-L, indicated that the IPR&D asset and goodwill should be tested for impairment. The Company recorded an impairment charge of $
(d) Fair Value Option
The Company has elected the fair value option for the Convertible Notes associated with the SEPA which are recorded in Notes payable – convertible, at fair value on the Company’s Consolidated Balance Sheets. The Company’s fair value option elections are made in accordance with the guidance in Accounting Standards Codification (“ASC”) 825, Financial Instruments, allowing entities to make an irrevocable election of fair value as the initial and subsequent measurement attributed for certain eligible financial assets and liabilities. The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument. Assets and liabilities measured at fair value pursuant to this guidance are required to be reported on the Company’s Consolidated Balance Sheets separate from instruments using another accounting method.
The Convertible Notes were initially recorded at fair value, which equaled the net proceeds received after the
(e) Recent Accounting Pronouncements
Unless otherwise discussed, the Company believes that recently issued accounting pronouncements will not have a material effect on its consolidated financial position, consolidated results of operations, and consolidated cash flows, or do not apply to its operations.
In November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general and administrative expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect that this change will have on its disclosures.
In December 2025, the FASB issued ASU 2025-10, “Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities.” This standard provides authoritative guidance for recognition, measurement, and presentation of government grants from a government to a business entity. The standard is effective for annual periods beginning after December 15, 2028, and interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-10 on its consolidated financial statements and related disclosures.
(3) Business Combination
On October 8, 2025, the Company completed the Acquisition in exchange for
10
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
The fair value of the consideration totaled approximately $
| | | |
Fair value of contingent consideration | | $ | |
Reimbursement right asset | | | ( |
Fair value of common stock issued | | | |
Fair value of preferred stock issued | | | |
Total Consideration Paid | | $ | |
The Company recorded the assets acquired and liabilities assumed as of the date of the Acquisition based on the information available at that date. The following table presents the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the Acquisition date:
| | | |
Assets acquired: | | | |
Cash | | $ | |
Prepaid expenses and other current assets | | | |
Property and equipment, net of depreciation | | | |
In-process research and development assets: Seviprotimut-L | | | |
Goodwill | | | |
Total assets acquired | | $ | |
| | | |
Liabilities assumed: | | | |
Accounts payable and accrued expenses | | $ | |
Deferred tax liability | | | — |
Total liabilities assumed | | | |
Net assets acquired | | $ | |
The following table summarizes the Company’s intangible assets and goodwill acquired in connection with the Acquisition and their carrying values as of September 30, 2026:
| | | | | | | | | |
| | | | | | | | Carrying Value | |
| | Acquisition Date | | | | | as of | ||
| | Level 3 | | | | | September 30, | ||
| | Fair Value | | Impairment | | 2026 | |||
| | | | | | | | | |
Seviprotimut-L | | $ | | | $ | ( | | $ | |
Total in-process research and development (IPR&D) | | $ | | | $ | ( | | $ | |
| | | | | | | | | |
Goodwill | | $ | | | $ | — | | $ | |
Goodwill of $
The Company first tested the Seviprotimut-L IPR&D asset and recorded an impairment charge of $
11
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
approval of
The Company then tested goodwill by comparing the estimated fair value of its single reporting unit with its carrying amount after the IPR&D impairment. The estimated fair value of the reporting unit of approximately $
(4) Fair Value Measurements
Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of the dates of the Company’s consolidated balance sheets herein. The carrying amount of cash, grant receivable, prepaid expenses and other current assets, and accounts payable and accrued expenses approximated their fair value due to their short-term or fixed arrangements nature. Warrant liabilities and contingent considerations are recorded based on their fair value.
Warrant Liability
The Series C Warrants are liability-classified and are remeasured at fair value each reporting period, a Level 3 measurement. The fair value at September 30, 2026 and December 31, 2025 was determined using the Black-Scholes model with the following assumptions:
| | | | |
Assumptions | | September 30, 2026 | | December 31, 2025 |
Risk-free rate | | | ||
Volatility | | | ||
Expiration date of Series C | | February 24, 2030 | | February 24, 2030 |
Remaining term in years | | | | |
Share Price | | $ | | $ |
Strike Price | | $ | | $ |
The change in fair value of the Series C Warrants of $
12
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
Convertible Note
The Company has elected the fair value option for the Convertible Notes issued to Yorkville (see Note 8). The fair value of the Convertible Notes at September 30, 2026 was determined using a Monte Carlo simulation that models the Company's stock price weekly, Yorkville's expected conversion behavior and the probability-weighted outcomes of three scenarios: the notes reaching maturity (
| | |
Assumptions | | September 30, 2026 |
Stock Price | | $ |
Fixed Price | | $ |
Floor Price | | $ |
Equity Volatility | | |
Risk-free rate | | |
Remaining term | | |
Scenario probabilities | | Maturity |
Recovery in dissolution | |
Contingent Consideration
The contingent consideration liability arising from the Acquisition is a Level 3 measurement determined using a discounted cash flow analysis whose significant inputs are the probability and expected timing of each milestone event and the discount rate. The milestone events, all related to Seviprotimut-L, are:
| | | | | | |
| | Expected | | | | |
| | Achievement | | | | |
Milestone Event | | Date | | Amount | ||
1. First dosing in a patient in a U.S. Phase 3 Non-Confirmatory Clinical Study | | | June 30, 2029 | | $ | |
2. Achievement of applicable primary endpoint in U.S. Phase 3 Non-Confirmatory Clinical Study | | | June 30, 2036 | | $ | |
3. First submission of Biologics License Application (“BLA”) to the U.S. FDA | | | June 30, 2042 | | $ | |
4. First approval by the FDA of a BLA | | | June 30, 2043 | | $ | |
| | | | |
Assumptions | | September 30, 2026 | | December 31, 2025 |
Expected achievement date of milestone event #1 | | June 30, 2029 | | June 30, 2029 |
Probability of achieving milestone event #1 | | | ||
Discount rate applied to milestone event #1 | | | ||
Expected achievement date of milestone event #2 | | June 30, 2036 | | June 30, 2036 |
Probability of achieving milestone event #2 | | | ||
Discount rate applied to milestone event #2 | | | ||
Expected achievement date of milestone event #3 | | June 30, 2042 | | June 30, 2042 |
Probability of achieving milestone event #3 | | | ||
Discount rate applied to milestone event #3 | | | ||
Expected achievement date of milestone event #4 | | June 30, 2043 | | June 30, 2043 |
Probability of achieving milestone event #4 | | | ||
Discount rate applied to milestone event #4 | | |
13
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of the dates indicated.
September 30, 2026
| | | | | | | | | | | | |
| | Level 1 | | Level 2 | | Level 3 | | Total | ||||
Liabilities | | | | | | | | | | | | |
Notes Payable - Convertible | | $ | — | | $ | — | | $ | | | $ | |
PIPE warrants - Series C | | | — | | | — | | | | | | |
Contingent consideration | | | — | | | — | | | | | | |
Total liabilities, at fair value | | $ | — | | $ | — | | $ | | | $ | |
December 31, 2025
| | | | | | | | | | | | |
| | Level 1 | | Level 2 | | Level 3 | | Total | ||||
Liabilities | | | | | | | | | | | | |
PIPE warrants - Series C | | $ | — | | $ | — | | $ | | | $ | |
Contingent consideration | | | — | | | — | | | | | | |
Total liabilities, at fair value | | $ | — | | $ | — | | $ | | | $ | |
| | | | | | | | | | | | | | | | |
| | Notes Payable | | | Warrants | | Warrants | | Contingent | | Total | |||||
Level 3 Rollforward: | | Convertible | | | Series C | | Series D | | Consideration | | Liabilities | |||||
Balance, December 31, 2024 | | $ | — | | | $ | | | $ | | | $ | — | | $ | |
Additions | | | — | | | | — | | | — | | | | | | |
Change in fair value | | | — | | | | ( | | | | | | ( | | | |
Exercise of Series D warrants | | | — | | | | — | | | ( | | | — | | | ( |
Balance, December 31, 2025 | | | — | | | | | | | — | | | | | | |
Additions | | | | | | | — | | | — | | | — | | | |
Change in fair value | | | ( | | | | ( | | | — | | | ( | | | ( |
Repayments | | | ( | | | | — | | | — | | | — | | | ( |
Conversion of convertible promissory notes to common stock | | | ( | | | | — | | | — | | | — | | | ( |
Balance, September 30, 2026 | | $ | | | | $ | | | $ | — | | $ | | | $ | |
Nonrecurring fair value measurement
The Seviprotimut-L IPR&D asset was written down to its estimated fair value of $
(5) Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following:
| | | | | | |
| | September 30, | | December 31, | ||
| | 2026 | | 2025 | ||
Prepaid operating expenses | | $ | | | $ | |
Contract manufacturers and research organizations | |
| | |
| |
Insurance premiums | |
| | |
| |
Prepaid FICA | | | | | | |
| | $ | | | $ | |
14
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
(6) Receivable from Related Party
Under the Purchase Agreement, DEFJ agreed to reimburse the Company for up to $
(7) Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consisted of the following:
| | | | | | |
| | September 30, | | December 31, | ||
| | 2026 | | 2025 | ||
Professional and general consulting fees | | $ | | | $ | |
R&D-related – CMOs, CROs, supplies, equipment and consulting | |
| | |
| |
General expenses | |
| | |
| |
Insurance premiums | |
| | |
| |
Payroll and benefits | | | | | | |
Accrued license payments | | | | | | — |
| | $ | | | $ | |
At September 30, 2026, and December 31, 2025, the Company’s outstanding payables to CROs or CMOs included above were $
(8) Convertible Note and SEPA
On April 6, 2026, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited partnership, (“Yorkville”) pursuant to which it has the right (the “SEPA Option”) to sell to Yorkville up to $
Upon satisfaction of the conditions to Yorkville’s purchase obligations set forth in the SEPA, the Company may, at its sole discretion, direct Yorkville to purchase specified amounts of Common Stock. The purchase price per share for each Advance is set at
The SEPA Option was evaluated and determined to be a freestanding financial instrument which met the criteria to be accounted for as a derivative instrument. As of September 30, 2026, the Company determined the fair value of the SEPA Option was insignificant.
In connection with the SEPA, Yorkville also agreed to advance up to $
15
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
The first Pre-Paid Advance was disbursed to the Company on April 16, 2026. In exchange for the first Pre-Paid Advance, the Company issued to Yorkville a Convertible Note in the principal amount of $
The second tranche of the Pre-Paid Advance was disbursed to the Company on July 22, 2026, in exchange for the issuance to Yorkville of a Convertible Note in the principal amount of $
The Convertible Notes require monthly cash payments to Yorkville if the daily VWAP of the Common Stock is below the Floor Price for five trading days during any period of seven consecutive trading days (an "Amortization Event"). Payments begin on the seventh trading day after the Amortization Event. Each payment equals
SEPA financing issuance costs, which are expensed as incurred under the fair value option, were $
(9) Grant Income
In September 2024, the Company received its second award (the “2024 Award”) from the National Cancer Institute of the National Institutes of Health (the “NIH”). The 2024 Award is a
16
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
trial activities in the Company’s clinical trial with its lead candidate, TTX-MC138. The total 2024 Award is for $
(10) Unleash License Agreement
On March 2, 2026, the Company entered into an Exclusive Licensing Agreement (the “Licensing Agreement”) with Unleash Immuno Oncolytics, Inc., a Delaware corporation, (“Unleash”) pursuant to which Unleash granted the Company a royalty-free, sublicensable global license to develop Unleash’s pre-clinical candidate program involving genetically-engineered adenoviruses to harness the immune system to fight cancer, as well as an exclusive, perpetual, irrevocable, worldwide, fully-paid up, royalty-free, sublicensable right and license to related technology. In consideration of the Licensing Agreement, the Company issued
Tungsten Advisors (together with its affiliates, “Tungsten”) acted as the financial advisor to the Company in connection with the Licensing Agreement. As compensation for services rendered by Tungsten, the Company issued
The fair value of the consideration totaled approximately $
| | | |
Fair value of preferred stock issued to Unleash | | $ | |
Fair value of preferred stock issued to Tungsten | |
| |
Total Consideration Paid | | $ | |
(11) Commitments and Contingencies
(a) License Agreements
The Company is party to exclusive license agreements with The General Hospital Corporation, d/b/a Massachusetts General Hospital, and, through Polynoma, with Sloan Kettering Institute for Cancer Research, under which it is obligated to pay minimum annual license fees, milestone payments upon the achievement of specified development and regulatory events (up to $
(b) Collaboration Agreements
Quantum Leap Healthcare Collaborative
17
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
In December 2025, the Company entered into a collaboration agreement with Quantum Leap Healthcare Collaborative to conduct a Phase 2a clinical trial of TTX-MC138. Payments under the agreement total approximately $
The University of Texas M. D. Anderson Cancer Center
The Company's collaboration agreement with The University of Texas M.D. Anderson Cancer Center, described in Note 10 to the audited consolidated financial statements included in the 2025 Annual Report on Form 10-K, is limited to MD Anderson's participation as a clinical site in the Company's Phase I/II trial and includes no minimum funding commitment.
(c) Litigation
The Company may from time to time be subject to claims by others under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, consolidated financial condition, and consolidated cash flows.
On April 24, 2026, Wheeler Bio, Inc. ("Wheeler") filed a complaint in the Supreme Court of the State of New York against Polynoma and the Company (the "Wheeler Action") asserting breach of contract against Polynoma and intentional interference with contractual relations against the Company, arising from Polynoma's termination on October 1, 2025 of a statement of work under a contract development and manufacturing agreement. On July 30, 2026, the court compelled arbitration and stayed the litigation. On November 6, 2026, the Company, Polynoma and Wheeler entered into a settlement and mutual release agreement under which the Wheeler Action was discontinued with prejudice and the parties released all claims, without admission of liability. The Company made
The Company is also disputing a claim by an investment bank that it is entitled to fees. The Company is not aware of any other pending or threatened claims that could have a material adverse effect on its financial position, results of operations or cash flows.
(d) Contingent Value Rights
In connection with the Acquisition, the Company issued contingent value rights ("CVRs") to holders of Common Stock as of October 20, 2025, entitling them in the aggregate to
(e) Separation Agreement
In September 2026, the Company's Chief Financial Officer resigned and entered into a separation agreement with the Company providing for severance of $
18
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
(12) Stockholders’ Equity (Deficit)
(a) Capital Stock
The Company is authorized to issue
(b) Preferred Stock
The terms of the Company's Series A, Series B and Series C Non-Voting Convertible Preferred Stock are described in Note 12 to the audited consolidated financial statements included in the 2025 Annual Report on Form 10-K (Series A and B) and in Note 10 to these condensed consolidated financial statements (Series C).
On April 6, 2026, the Company paid a one-time dividend in kind on the Series A Preferred Stock at a rate of
Prior to April 8, 2026, the Series B Preferred Stock was not convertible and was classified within permanent equity. Effective April 8, 2026, the Series B Preferred Stock became convertible and certain settlement provisions became operative that, in circumstances not solely within the Company's control, could have required cash settlement. Accordingly, the Company reclassified the carrying amount of the Series B Preferred Stock of approximately $
On July 20, 2026, the Company's stockholders approved the conversion of the Series A, Series B and Series C Preferred Stock into Common Stock. Between July 20, 2026 and August 10, 2026, all outstanding shares of each series converted into an aggregate of
(c) Issuances of Common Stock
During the nine months ended September 30, 2026, the Company issued
19
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
(13) Warrants
The following table summarizes the Company's outstanding warrants at September 30, 2026. The Series C Warrants are liability-classified and are remeasured at fair value each reporting period (see Note 4); all other warrants are equity-classified.
| | | | | | | |
| | Number | | Exercise Price | | | |
Description | | of Shares | | Per Share | | Expiration | |
February 2023 Placement Agent Warrants |
| | | $ | | | February 2028 |
February 2023 Consultant Warrants |
| | | | | | February 2028 |
September 2023 Underwriter Warrants |
| | | | | | September 2028 |
October 2023 Underwriter Overallotment Warrants |
| | | | | | September 2028 |
December 2023 Placement Agent Warrants |
| | | | | | December 2028 |
January 2024 Warrants |
| | | | | | July 2027 |
January 2024 Warrants |
| | | | | | July 2027 |
January 2024 Placement Agent Warrants |
| | | | | | July 2027 |
July 2024 Placement Agent Warrants |
| | | | | | July 2029 |
December 2024 Series C Warrants |
| | | | | | February 2030 |
March 2025 Offering Warrants |
| | | | | | March 2030 |
March 2025 Placement Agent Warrants |
| | | | | | March 2030 |
(14) Share-Based Compensation
Stock Option Plans
The Company's 2020 Stock Option and Incentive Plan (the “2020 Plan”) and 2021 Stock Option and Incentive Plan (the "2021 Plan") are described in Note 14 to the audited consolidated financial statements included in the 2025 Annual Report on Form 10-K.
20
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
Of options outstanding at September 30, 2026, approximately
| | | | | | | |
| | | | Weighted | | | |
| | | | average | | Weighted | |
| | | | exercise | | average | |
| | Number of | | price | | contractual | |
| | shares | | per share | | term (years) | |
Outstanding at December 31, 2024 |
| |
| $ | |
| |
Granted |
| — | | | — |
| — |
Exercised |
| — | | | — |
| — |
Forfeited |
| ( | | | |
| — |
Outstanding at December 31, 2025 |
| | | | |
| |
Granted |
| | | | |
| — |
Exercised |
| — | | | — |
| — |
Forfeited |
| — | |
| — |
| — |
Outstanding at September 30, 2026 |
| | | $ | |
| |
In September 2026, the Company granted options to purchase
Valuation Assumptions
The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:
| | |
| | Nine Months Ended |
| | September 30, 2026 |
Risk-free interest rate |
| |
Expected term (in years) |
| |
Expected volatility |
| |
Expected dividend yield |
| — |
Fair value per share of underlying stock | | $ |
The expected term is determined using the simplified method, which represents the average of the contractual term of the options and the weighted average expected vesting period. The risk-free interest rate is determined by reference to the United States Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the option. The expected stock volatility rate is based on the volatility rates of comparable publicly held companies over a period equal to the expected term of the option. The Company also utilizes its limited available historical volatility, to a lesser weight, in its expected stock volatility calculation. The Company utilizes a dividend yield of
Employee Stock Purchase Plan
The Company's 2021 Employee Stock Purchase Plan (the "ESPP") permits eligible employees to purchase shares of common stock at a discount through payroll deductions. The number of shares available under the ESPP increases annually under the plan's evergreen provision; after giving effect to the reverse stock splits.
21
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
(15) Net Loss per Share
Basic net loss per share is determined by dividing net loss attributable to common stockholders, which reflects the accrual of paid-in-kind dividends on the Series A Preferred Stock, by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share would include the effect, if any, of securities that could result in the issuance of additional shares of common stock ("Contingent Securities"), which at September 30, 2026 consisted of outstanding warrants (Note 13), stock options (Note 14) and the Convertible Notes (Note 8) and, for the portion of the periods before their conversion in July and August 2026, the Series A, Series B and Series C Preferred Stock on an as-converted basis (Note 12). The Company reported net losses for the three and nine months ended September 30, 2026 and 2025. Basic and diluted net loss per share attributable to common stockholders are therefore the same in each period, because including the Contingent Securities in the computation of diluted weighted-average shares outstanding would have been antidilutive.
The following table sets forth the computation of basic and diluted net loss per share:
| | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, | | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | | ||||
Basic and diluted net loss per share | | | | | | | | | | | | | |
Net loss attributable to common stockholders | | $ | ( | | $ | ( | | $ | ( | | $ | ( | |
Weighted-average common shares outstanding | |
| | |
| | |
| | |
| | |
Net loss per share | | $ | ( | | $ | ( | | $ | ( | | $ | ( | |
(16) Income Taxes
The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of the dates of the Company’s consolidated balance sheets herein, the Company had a full valuation allowance against deferred tax assets with the exception of the “naked” credit from amortization for tax purposes of indefinite-lived intangible assets of Goodwill and IPR&D. The Company booked a benefit of approximately $
The Company is subject to the provisions of ASC 740-10-25, “Income Taxes” (“ASC 740”). ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at the dates of the Company’s consolidated balance sheets herein.
(17) Segment Reporting
The Company operates as a single operating and reportable segment: the research and development of therapeutics for the treatment of cancer. The Company's chief operating decision maker ("CODM") is its Chief Executive Officer, who assesses performance and allocates resources based on consolidated net loss. The significant expense categories regularly provided to the CODM are research and development and general and administrative expenses, as presented in the condensed consolidated statements of operations. The impairment of in-process research and development of $
(18) Subsequent Events
The Company evaluated subsequent events through November 16, 2026, the date on which these condensed consolidated financial statements were issued.
22
Table of Contents
TRANSCODE THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
September 30, 2026
(Unaudited)
Strategic Review
On October 28, 2026, the Company announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the Company and its oncology portfolio, including TTX-MC138. There can be no assurance that the process will result in any transaction.
Convertible Notes Waiver and Prepayment
On October 1, 2026, the Company and Yorkville executed the waiver of Amortization Events through October 31, 2026 described in Note 8. Since the waiver period ended, the Company's daily VWAP has remained below the Floor Price, and an Amortization Event occurred in November 2026. Unless the event is waived, the Company is required to make the monthly cash payments described in Note 8. The Company is in discussions with Yorkville, and there can be no assurance that it will obtain a waiver or other relief (see Note 1).
Wheeler Settlement
On November 6, 2026, the Company settled the Wheeler Action without any cash payment (see Note 11).
23
Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our consolidated financial condition and consolidated results of operations together with the “Consolidated Financial Statements” section of this Quarterly Report on Form 10-Q including the related notes appearing elsewhere in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those set forth in the “Cautionary Note Regarding Forward Looking Statements” and “Risk Factors” sections of this Quarterly Report, our actual results could differ materially from the consolidated results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Company Overview
TransCode is an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. We obtained our second principal therapeutic candidate, Seviprotimut-L, in connection with our acquisition of Polynoma as discussed below.
In 2023, we conducted a Phase 0 clinical trial with TTX-MC138 in one patient with advanced solid tumors. The intent of the Phase 0 trial was to demonstrate quantitative delivery of radiolabeled TTX-MC138 to metastatic lesions. In September 2024, we commenced a Phase I/II clinical trial with TTX-MC138 which substantially met its primary safety endpoint by the end of 2025. Analysis of the Phase I/II clinical trial results is ongoing. We have recently initiated a Phase 2a clinical trial and expect patients to begin enrolling in the first half of 2027. The revised timing reflects delays due to the collaboration and refocused efforts on recruitment.
Polynoma Acquisition. On October 8, 2025, we entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with DEFJ, LLC, a Delaware limited liability company, (“DEFJ”) pursuant to which we acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company, (“ABCJ”) (such transaction, the “Acquisition”). Prior to the Acquisition, ABCJ was a wholly-owned subsidiary of DEFJ and an indirect wholly-owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc., a listed entity on the Main Board of the Hong Kong Stock Exchange (“CKLS”). In the Acquisition, we issued to DEFJ 83,285 shares of Common Stock and 1,152.9568 shares of Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"). We also issued 59.2254 shares of Series A Preferred Stock in payment of transaction costs related to the Acquisition and, on April 6, 2026, 29.8895 shares of Series A Preferred Stock to DEFJ as a payment-in-kind dividend. Each share of Series A Preferred Stock was convertible into 10,000 shares of Common Stock, and all 1,242.0717 outstanding shares converted into 12,420,717 shares of Common Stock between July 20 and August 10, 2026.
ABCJ owns 100% of the issued and outstanding membership interests of Polynoma, LLC, a Delaware limited liability company, (“Polynoma”) previously headquartered in San Diego, California. Polynoma is an immuno-oncology focused biopharmaceutical company developing Seviprotimut-L, an investigational polyvalent antigen vaccine intended to reduce the risk of recurrence of cancer in patients with stage IIB and IIC melanoma who have limited options. Seviprotimut-L has completed a Phase III clinical trial and has been safely administered in clinical trials to more than 1,000 patients. Seviprotimut-L is a novel allogeneic, polyvalent partially-purified shed antigens vaccine (alum adjuvanted) for the adjuvant treatment of Stage IIB and IIC melanoma patients age 60 years and younger. Seviprotimut-L is derived from three proprietary human melanoma cell lines. Seviprotimut-L works by stimulating both humoral and cellular immune responses. It has completed an initial Phase 3 clinical trial and has been administered to approximately 1,000 patients in clinical trials.
We intend to work on developing both TTX-MC138 and, depending on funding availability, Seviprotimut-L, with our initial focus on advancing TTX-MC138 in the Phase 2a clinical trial. We are evaluating various approaches for continuing development of Seviprotimut-L which will require additional CMC work (chemistry, manufacturing and control) as well as at least one additional Phase III clinical trial. We believe there may be potential to augment Seviprotimut-L's focus with TTX-MC138 by addressing micrometastases in stage IIB and IIC melanoma patients.
24
Table of Contents
Concurrent with the Acquisition, we entered into an Investment Agreement (the “Investment Agreement”) with DEFJ. Pursuant to the Investment Agreement, DEFJ agreed to purchase, and we agreed to issue and sell, in a private placement an aggregate of 223.7337 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”) at a price per share of $111,740, for an aggregate purchase price of approximately $25 million. The aggregate purchase price consisted of a cash subscription of $20 million paid on October 8, 2025, and issuance by DEFJ of a promissory note (the “Promissory Note”) in the aggregate principal amount of approximately $5 million (together, the “Investment”). The Promissory Note accrued interest at a rate of 4% per annum, calculated as simple interest on a 365-day year. The principal and accrued interest were paid on December 30, 2025. Each share of Series B Preferred Stock is convertible into 10,000 shares of Common Stock.
Unleash Licensing Agreement. In March 2026, we entered into the Unleash Licensing Agreement with Unleash pursuant to which we acquired a pre-clinical candidate program involving genetically-engineered adenoviruses to harness the immune system to fight cancer, as well as an exclusive, perpetual, irrevocable, worldwide, fully-paid up, royalty-free, sublicensable right and license to related technology.
As consideration for the Unleash Licensing Agreement, pursuant to an Equity Issuance and Registration Rights Agreement with Unleash (the “Unleash Registration Rights Agreement”), we issued to Unleash 1,136,364 shares of our Series C Non-Voting Convertible Preferred Stock. Additionally, we issued 77,840 shares of our Series C Non-Voting Convertible Preferred Stock to Tungsten Advisors (together with its affiliates, “Tungsten”) as compensation for services rendered by Tungsten. Conversion of the Series C Preferred Stock required approval by our stockholders in accordance with the listing rules of Nasdaq which approval was obtained on July 20, 2026. Between July 20, 2026, and August 10, 2026, each share of Series C Preferred Stock has converted into one share of our Common Stock.
Other Drug Candidates
In addition to TTX-MC138 and Seviprotimut-L, we have a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. TTX-siPDL1 is an siRNA-based modulator of programmed death-ligand 1, or PD-L1. TTX-RIGA is an RNA-based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment. TTX-siMYC is a siRNA-based inhibitor of c-MYC, a widely expressed but currently undruggable oncogene. The immune-oncology program we licensed from Unleash includes oncolytic virus constructs initially being developed for the treatment of muscle invasive bladder cancer.
Targeted Therapeutic Delivery Background
For decades, ribonucleic acid, or RNA, has been a topic of investigation by the scientific community as a potentially attractive therapeutic modality because it can target any gene, and it lends itself to rational and straightforward drug design. RNA-based therapeutics are highly selective to their targets and potentially applicable to a broad array of previously undruggable targets in the human genome. We believe that one of the major challenges to widespread use of RNA therapeutics in oncology and other indications has been the inability to deliver these molecules inside cells.
To customize development of RNA therapeutics, we developed a design engine that is modular at both the levels of the core nanoparticle and the therapeutic loading. The size, charge, and surface chemistry of the core iron oxide nanoparticle are designed so that it can be tuned to optimize the particles for the intended target and therapeutic load. The therapeutic load is designed to consist of synthetic oligonucleotides and other molecular moieties such as proteins, peptides, radionuclides, and small molecules that can be adapted to the specific approach being developed. The approach can range from RNA interference, or RNAi, including small interfering RNAs, antisense oligonucleotides, and non-coding RNA mimics to Pattern Recognition Receptors such as RIG-I. We believe the TTX platform can further be used for developing targeted radiolabeled therapeutics and diagnostics and other custom products targeting known and novel biomarkers and other genetic elements as they are discovered and validated.
Our TTX platform is designed to overcome extracellular and intracellular delivery issues of stability, efficiency, and immunogenicity faced by existing lipid and liposomal nanoparticle platforms while optimizing targeting of and accumulation in tumors and metastases. We believe the ability to deliver targeted therapeutics inside tumors and metastases will potentially allow us to target genes and other important biomarkers for cancer treatment that have until now remained undruggable using other delivery systems.
25
Table of Contents
TTX Delivery System
The therapeutic potential of RNA in oncology has remained an unrealized promise due in large part, we believe, to the difficulty in safely and effectively delivering oligonucleotides, i.e., synthetic RNA molecules, to tumors. We believe we are now closer to solving this challenge by means of our TTX platform.
Our TTX technology has gone through more than 20 years of research and development, or R&D, and optimization, including 12 years at Harvard Medical School and the Massachusetts General Hospital, by our scientific co-founders prior to company formation.
Our TTX nanocarrier is designed to be tunable to certain specifications to deliver therapeutic oligonucleotides to RNA targets in tumors and metastases without compromising the integrity of the oligonucleotide. We believe our TTX nanocarriers differentiate us from competitive delivery approaches, many of which rely on lipid particles or chemical structures, such as GalNAc. These competitive delivery approaches effectively target hepatocytes in the liver but not tumors and metastases.
Our TTX delivery platform is also designed to minimize early kidney and liver clearance, which we expect to translate into a long circulation half-life that allows for efficient accumulation in tumors and metastases.
Nanoparticles similar in formulation to ours have an excellent clinical safety record of low toxicity and immunogenicity. Because their iron core is magnetic and visible with magnetic resonance imaging, or MRI, they have the additional benefit of enabling quantification of the delivery of the particles to target organs. Our nanoparticles carry functional groups to provide stable links to the therapeutic oligonucleotides of interest through covalent bonds.
The small hydrodynamic size and the charge of the resulting nanoparticles are designed to maximize distribution throughout the tumor microvasculature, extravasation into the interstitium of tumors and metastases, and uptake by tumors. The physicochemical properties of the nanoparticles are expected to further facilitate their rapid uptake by tumors by exploiting the high metabolic activity of cancer cells, a process analogous to the mechanism behind the systemic loading of metastatic cancer cells with fluorodeoxyglucose for diagnostic Positron Emission Tomography, or PET. We believe the combined result of a hydrodynamically-favored distribution and a metabolically-triggered uptake will result in the enhanced ability of our nanoparticles to access genetic targets inside tumors.
Advancing new RNA therapies through a modular approach
In September 2021, research conducted by MGH was published in Cancer Nanotechnology, entitled “Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer.” This paper reported on an MGH study using a radiolabeled derivative of TTX-MC138 (referred to in the paper as MN-anti-miR10b). In this study, TTX-MC138 was tagged with copper-64, or Cu-64. As a result, highly sensitive and specific quantitative determination of pharmacokinetics and biodistribution, as well as observation of delivery of the radiolabeled TTX-MC138 to metastases, was made in laboratory tests using noninvasive PET-MRI. The key results of the study suggest that when injected intravenously, TTX-MC138 accumulates in metastatic lesions. These results suggest that our TTX platform delivers its therapeutic candidate as intended and support clinical evaluation of TTX-MC138. In addition, the MGH investigation describes a microdosing PET-MRI approach to measure TTX-MC138 biodistribution in cancer patients and its delivery to clinical metastases. (Microdoses are minute, subpharmacologic doses of a test compound, not greater than 100 micrograms.) The capacity to carry out microdosing PET-MRI studies in patients under an exploratory IND, or eIND, application could be important because they have the potential to support additional clinical trials we may propose for FDA consideration. The research described in this paper, published by Dr. Zdravka Medarova, our Chief Scientific Officer and scientific co-founder, and others, describes what we believe is an effective approach to assessing delivery of TTX-MC138 in metastatic cancer patients. Since the PET-MRI technique is sensitive enough to determine the concentration of radiolabeled drug candidate in the sub-picomolar range, microgram quantities of the radiolabeled drug
26
Table of Contents
candidate are believed to be sufficient to perform such a study in humans. We believe this capability has significant advantages in the initial phases of drug development.
Dr. Medarova’s paper suggests that the radiolabeling does not impact tumor cell uptake or the ability of TTX-MC138 to engage its target. The paper also shows that the biodistribution of radiolabeled TTX-MC138, when injected at a microdose, reflects its biodistribution at the level of a therapeutic dose.
These key findings informed the design of our Phase 0 microdose clinical trial with radiolabeled TTX-MC138 which we believe offered numerous potential advantages:
| (i) | allowed more precise quantitation of the amount of TTX-MC138 delivered to the metastatic lesions because of the higher sensitivity and quantitative accuracy of positron emission tomography; |
| (ii) | permitted measurement of the pharmacokinetics and biodistribution of TTX-MC138 not only in the metastatic lesions but in other tissues throughout the body, potentially informing Phase I/II clinical trial designs by allowing us to determine drug candidate uptake and clearance from vital organs; |
| (iii) | supported assessment of pharmacokinetic endpoints, potentially informing dosing for clinical trials. Specifically, because of the high sensitivity and quantitative nature of PET-MRI, we obtained information suggesting what drug concentration in the metastatic lesions over time could be which we then could assess relative to the effective dose used in our preclinical studies; and |
| (iv) | further informed clinical trial designs to potentially incorporate patient inclusion criteria in those designs. |
Because of the potential benefits from a microdose Phase 0 clinical trial, and reflecting the studies described in Cancer Nanotechnology, our First-in-Human Phase 0 trial was designed to deliver a microdose of our therapeutic candidate. Results from the trial suggest the validity of our TTX pipeline for drug delivery generally, potentially opening-up additional relevant RNA targets that have been previously undruggable.
SBIR Awards
In April 2021, we received a Fast-Track Small Business Innovation Research award, or SBIR Award, from the National Cancer Institute that provided approximately $2.4 million to fund a two-phased research partnership between us and Massachusetts General Hospital. The program commenced in April 2021 and ended in March 2024.
In September 2024, we received our second NIH Award (the “2024 Award”) from the National Cancer Institute of the NIH. The 2024 Award is a Direct to Phase II SBIR Award to support IND-enabling and clinical trial activities in our clinical trial with TTX-MC138 over two years. The total 2024 Award is for $1,999,972 of which $1,011,207 applies to the first year and $988,765 applies to the second year.
Recent Developments
Phase I/II Clinical Trial
We commenced a Phase I/II clinical trial with TTX-MC138 in September 2024 at MD Anderson and three other clinical trial sites. This trial has been designed as a multicenter, open-label, dose-escalation and dose-expansion study in patients with advanced solid tumors.
The Phase 1a stage of this trial involved administration of escalating therapeutic dose levels of our drug candidate in four cohorts of an aggregate of 16 patients. No significant safety or dose limiting toxicities have been reported in the trial. To date, approximately 86 doses of TTX-MC138 have been administered to the 16 patients, all of whom had advanced solid tumors. Three patients remain on trial. The median duration of treatment is 79 days. Importantly, the duration on study for all patients in this trial ranged from two to 22 cycles of treatment, indicative of tolerability and disease control. Data from this trial demonstrated evidence of dose response over a wide dose range, consistent with preclinical results and our Phase 0 clinical trial. Key assessments in the clinical trial characterize the
27
Table of Contents
safety, pharmacokinetic, pharmacodynamic and anti-tumor activity of TTX-MC138 from which we have estimated a maximum tolerated dose, or MTD, and which suggest that the mechanism of action of TTX-MC138 is on target. The trial also is exploring the effect of TTX-MC138 on biomarker expression, which may include miR-10b expression, and miR-10b downstream targets (RNA sequencing). Clinical assessments to further evaluate TTX-MC138 include clinical laboratory exams, CT scan assessments, and response assessments per RECIST criteria.
We recently initiated a Phase 2a clinical trial to evaluate TTX-MC138 in patients with ct-DNA positive colorectal cancer with Minimal Residual Disease (MRD), a setting characterized by significant unmet need with the potential to intervene before metastatic recurrence. The Phase 2a trial is being conducted in collaboration with Quantum Leap Health Care Collaborative (“Quantum Leap”) as part of its PRE-I-SPY clinical trial platform. The PRE-I-SPY program incorporates TTX-MC138 into a clinical trial designed as a multicenter, open-label, one-year treatment duration with one year follow up. The trial will evaluate event-free survival, ctDNA dynamics and pharmacokinetics of TTX-MC138 in up to 45 patients who (i) have stage I-III adenocarcinoma of the colon or rectum and are ctDNA positive with minimal residual disease detected by tumor-informed ctDNA assays, (ii) have completed standard curative-intent therapy, and (iii) show no radiographic evidence of recurrence or metastasis. This trial was initiated in the second quarter 2026. In October 2026, the Company announced a collaboration with Natera, Inc. to identify patient populations who meet the trial’s MRD-positive eligibility criteria more efficiently, streamline site-level identification, and optimize the pace and quality of enrollment for the study. With the collaboration and refocused efforts on recruitment, initial patient enrollment is expected in the first half of 2027. The revised timing reflects delays due to the collaboration and refocused efforts on recruitment. Dr. Paula Pohlmann of the MD Anderson Cancer Center is the Principal Investigator. The study is being conducted under a Quantum Leap IND and cross-referenced to our IND. The total amount of the Quantum Leap agreement is approximately $7.3 million payable against milestones tied to Quantum Leap’s performance under the terms of the collaboration agreement.
Yorkville Financing
On April 6, 2026, we entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited partnership, (“Yorkville”) pursuant to which we have the right to sell to Yorkville up to $14 million of shares of Common Stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA (the “Commitment Amount”). Sales of Common Stock to Yorkville under the SEPA, and the timing of any such sales, are at our option, and we are under no obligation to sell any shares of Common Stock to Yorkville under the SEPA.
Upon satisfaction of the conditions to Yorkville’s purchase obligations set forth in the SEPA, we may, at our sole discretion, direct Yorkville to purchase specified amounts of Common Stock. The purchase price per share for each Advance is set at 97% of the lowest daily VWAP during the three consecutive trading days beginning on the date upon which the Advance Notice is delivered. Actual sales of Common Stock to Yorkville under the SEPA will depend on a variety of factors including some to be determined by us, in our sole discretion, from time to time, which may include, among other things, market conditions, the trading price of the Common Stock and our determinations as to appropriate sources of funding for our business and operations.
In connection with the SEPA, Yorkville also agreed to advance to us up to $6.0 million, less certain amounts as described below, to be paid in two tranches (each, a “Pre-Paid Advance” and, together, the “Pre-Paid Advances”), in exchange for our issuance to Yorkville of convertible promissory notes (each, a “Convertible Note” and, together, the “Convertible Notes”). Pursuant to the Convertible Notes and the SEPA, Yorkville may convert all or any portion of the outstanding principal amount, accrued but unpaid interest, and other amounts outstanding under the Convertible Notes into shares of Common Stock, at any time and from time to time during the term of the Convertible Notes.
The first Pre-Paid Advance was disbursed to us on April 16, 2026. In exchange for the first Pre-Paid Advance, we issued to Yorkville a Convertible Note in the principal amount of $1.0 million (the “First Convertible Note”), sold with a purchase price discount of 5.0% (or $50,000). The First Convertible Note is convertible into Common Stock at the lower of (i) $10.71 per share and (ii) 95% of the lowest daily VWAP during the seven consecutive trading days immediately preceding the conversion date, but in no event lower than 20% of last reported trading price of our Common Stock on Nasdaq as quoted by Bloomberg (the “First Convertible Note Conversion Price”) as of the trading day immediately prior to the date of the SEPA (the “Floor Price”). After accounting for the purchase price discount, we received gross proceeds of $950,000 from the sale of the First Convertible Note.
28
Table of Contents
The second tranche of the Pre-Paid Advance was disbursed to the Company in exchange for the issuance to Yorkville of a Convertible Note in the principal amount of $5.0 million (the “Second Convertible Note”). The Second Convertible Note was issued with a purchase price discount of 5.0% (or $250,000) and is convertible into Common Stock at the lower of (i) $9.76 per share and (ii) 95% of the lowest daily VWAP during the seven consecutive trading days immediately preceding the conversion date, but in no event lower than the Floor Price (the “Second Convertible Note Conversion Price,” and together with the First Convertible Note Conversion Price, the “Conversion Price”). The Second Convertible Note was issued on July 22, 2026, following our receipt of stockholder approval to issue shares of Common Stock to Yorkville under the SEPA in excess of the Exchange Cap (defined below). After accounting for the purchase price discount, we received gross proceeds of $4,750,000 pursuant to the Second Convertible Note.
Interest on the outstanding balances of the Convertible Notes accrues at an annual rate of 5.0%, subject to an increase to 18% upon an event of default as described in the Convertible Notes. The maturity date of each Convertible Note is 18 months from the date upon which the Convertible Note was issued. The applicable maturity date of each Convertible Note may be extended by us, at our option, for a period of six months on two occasions by providing written notice to Yorkville. On the applicable maturity date, any portion of the outstanding principal amount and accrued but unpaid interest that remains outstanding on such Convertible Note will automatically be converted into Common Stock at the then applicable Conversion Price, provided that if any Equity Condition (as defined in the Form of Promissory Note ) is not satisfied, the applicable maturity date will be automatically extended until all Equity Conditions have been satisfied.
Yorkville may not own more than 9.99% of our outstanding Common Stock at any time, unless it provides written notice of its intention to increase this limit, effective after 65 days.
Amortization Event, Prepayment and Waiver
Under the terms of the Convertible Notes, an “Amortization Event” occurs if the daily VWAP of our common stock is below the $1.72 Floor Price for five trading days during any period of seven consecutive trading days. From September 11, 2026 to September 30, 2026, the daily VWAP was below the Floor Price on 10 of 14 trading days.
On September 30, 2026, the conditions for an Amortization Event were met and we made a prepayment of $840,975 under Section 1(f) of the Convertible Notes, consisting of $759,000 of principal, a $75,900 prepayment premium and $6,075 of accrued interest, in exchange for Yorkville's waiver of any Amortization Event occurring through October 31, 2026. Following the prepayment, approximately $4.1 million of aggregate principal remained outstanding under the Convertible Notes.
If an Amortization Event occurs after the waiver period, we would be required to make monthly cash payments to Yorkville, beginning on the seventh trading day after the event. Each payment would equal 18% of the outstanding principal as of the Amortization Event date, plus a 10% premium on the principal paid and accrued interest. Payments would continue until the Convertible Notes are repaid, or until our daily VWAP exceeds the Floor Price for ten consecutive trading days. The Company’s daily VWAP has remained below the Floor Price since October 31, 2026, and the Company has been in discussions with Yorkville regarding the Convertible Notes.
Sponsored Research Agreement
On April 11, 2026, the Company entered into a Sponsored Research Agreement (the “SRA”) with Michigan State University (“MSU”) pursuant to which MSU will conduct certain research projects in collaboration with the Company. There are no upfront financial obligations on the Company under the SRA. The Company will pay MSU agreed upon costs for conduct of the research. Each project under the SRA will have its own budget and payment schedule, with payments generally due monthly upon receipt of invoices from MSU.
MGH License Amendment
Effective August 15, 2025, we and The General Hospital Corporation, d/b/a Massachusetts General Hospital, (“Licensor”) further amended our 2018 License (the “Second Amendment”) to revise certain diligence requirements and milestone payments. Pursuant to the 2018 License (the License”), we licensed the exclusive rights to certain intellectual property to support development of our therapeutic candidates. In connection with the Second Amendment, we paid the Licensor a license amendment fee of $75,000. The
29
Table of Contents
Second Amendment revised certain one-time milestone payments to be made by us to the Licensor for Products and Processes covered by the License as follows:
| (i) | a certain dollar amount within sixty (60) days following dosing of the first patient in the first Phase II clinical trial for a Therapeutic Product or Therapeutic Process covered by the License; |
| (ii) | a certain dollar amount within sixty (60) days following dosing of the first patient in the first Phase III clinical trial for a Therapeutic Product or Therapeutic Process covered by the License; and |
(iii) | a certain dollar amount within sixty (60) days following the First Commercial Sale (as defined in the License) for a Therapeutic Product or Therapeutic Process covered by the License. |
In addition, upon the occurrence of a Change of Control Liquidity Event (as defined in the Second Amendment), we shall pay Licensor up to a certain dollar amount.
Natera Collaboration
On October 13, 2026, we announced a strategic collaboration with Natera, Inc. (“Natera”) to support enrollment in our Phase 2a clinical trial of TTX-MC138 in patients with colorectal cancer (“CRC”). We expect to use Natera’s Signatera™ molecular residual disease (“MRD”) test to identify patients who have completed curative-intent therapy, remain MRD-positive, and have no radiographic evidence of disease, and who are therefore eligible for enrollment in the trial. The collaboration is intended to help identify patients who meet the trial’s MRD-positive eligibility criteria more efficiently, streamline identification of eligible patients at participating clinical sites, and support the pace and quality of enrollment.
Nasdaq Listing
On May 19, 2026, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, reported stockholders’ equity of $1,251,427, which is below the Stockholders’ Equity Requirement.
Following our stockholders’ approval at a meeting of stockholders held on July 20, 2026, of the conversion of our Series A Preferred Stock, Nasdaq confirmed that we had regained compliance with the Stockholders’ Equity Requirement. As a result, and subject to our remaining in compliance with Nasdaq listing requirements, our stock will continue to be listed on the Nasdaq.
Financial Operations Overview
We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have limited experience with clinical trials, have not obtained any regulatory approvals to sell any products, have not manufactured any drug candidate at commercial-scale, or conducted sales and marketing activities. We have funded our operations to date primarily with proceeds from our IPO, other equity financings including the Investment Agreement, our SBIR Awards and the issuance of convertible notes.
We have incurred significant operating losses since inception. Our net losses were approximately $131.9 million and $21.2 million for the nine months ended September 30, 2026 and 2025, respectively. At September 30, 2026, we had an accumulated deficit of approximately $229.8 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates for which there is no assurance of occurrence. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:
| Ø | advance clinical trials with TTX-MC138; |
30
Table of Contents
| Ø | pursue preclinical studies and initiate other clinical trials with TTX-MC138; |
| Ø | advance the development of our product candidate pipeline; |
| Ø | continue to develop and expand our proprietary TTX platform to identify additional product candidates; |
| Ø | support partnerships with industry and academic partners; |
| Ø | obtain new intellectual property and maintain, expand and protect our intellectual property; |
| Ø | seek marketing approvals for our product candidates that successfully complete clinical trials, if any; |
| Ø | hire or engage additional quality assurance, clinical, scientific, commercial and administrative personnel to increase our overall knowledge base, scientific expertise, experience and capabilities; |
| Ø | acquire or license additional product candidates or technologies; |
| Ø | expand our infrastructure and facilities to accommodate increased activities and personnel; |
| Ø | add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and our continued operation as a public company; and incur additional costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company. |
As a result, we will need substantial additional funding to support our continuing operations and pursue our business strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through sales of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we will likely need to consider cost reduction strategies, which may include, among others, amending, delaying, limiting, reducing, or terminating our development programs, and we may need to seek an in-court or out-of-court restructuring of our liabilities. In the event of such future restructuring activities, holders of our Common Stock and other securities would likely suffer a total loss of their investment.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of September 30, 2026, we had cash of approximately $4.6 million. We believe that this cash will be sufficient to support our operating expenses and capital expenditure requirements through approximately year end 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.
To finance our operations beyond that point, we will need to raise additional capital which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms we find acceptable, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. See “Liquidity and capital resources.”
Impact of global economic and political developments and global pandemics
The development of our product candidates or our operations could be disrupted and materially adversely affected by global economic or political developments. In addition, economic uncertainty in global markets caused by political instability and conflict, such as the ongoing conflicts in Ukraine and the Middle East, and economic challenges caused by global pandemics or other public health events, may lead to market disruptions, including significant volatility in commodity prices, credit and capital market instability and supply chain interruptions. Our business, consolidated financial condition and consolidated results of operations could be
31
Table of Contents
materially and adversely affected by adverse events in the global economy and capital markets resulting from these global economic conditions and circumstances, particularly if such conditions and circumstances are prolonged or worsen.
Although our business has not been materially impacted directly by these global economic and political developments to date, it is impossible to predict the extent to which we may be impacted in the short and long term, or the ways in which our business, consolidated financial condition and consolidated results of operations could be affected by any of the foregoing or other events which may occur in the future. Any such disruptions may also magnify the impact of other risks described herein or in our other filings with the SEC.
Components of our results of operations
Revenue
To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If development efforts for our product candidates are successful and result in regulatory approval of any product candidate, or license agreements with third parties, we may generate revenue in the future from product sales or licensing agreements. However, there can be no assurance as to when, if ever, we will generate any such revenue.
Operating expenses
Research and development expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of product candidates. We expense research and development costs as incurred, which at times include:
| Ø | expenses incurred in preclinical and clinical development, including manufacturing activities; |
| Ø | expenses incurred to conduct the preclinical studies and clinical trials related to seeking regulatory approval of market product candidates that have successfully completed clinical trials; |
| Ø | expenses incurred under agreements with contract research organizations, or CROs, conducting drug discovery work, preclinical studies, and clinical trials for us, and with contract manufacturing organizations, or CMOs, engaged to produce preclinical and clinical drug substance and drug product for our research and development activities; |
| Ø | other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and our preclinical studies, materials for our clinical trials, including manufacturing validation batches, as well as costs related to investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services; |
| Ø | payments made under third-party licensing, acquisition and option agreements; |
| Ø | personnel-related expenses for research and development personnel, including salaries, benefits, travel and other related expenses, and share-based compensation expense; |
| Ø | costs related to compliance with regulatory requirements; and |
| Ø | allocated facilities costs, including rent and utilities, and depreciation and other facilities or equipment expenses. |
We recognize external development costs based on an evaluation of the progress toward completion of specific tasks using information provided to us by our employees, consultants and service providers, including CROs and CMOs. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, the estimated level of service performed, and the associated costs incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Nonrefundable advance payments that we make for goods or services to be received or performed in the future in research and development activities are recorded as prepaid expenses. Such amounts are subsequently expensed as the
32
Table of Contents
related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.
We seek to track our research and development expenses on a program-by-program basis. Our direct external research and development expenses comprise primarily payments to outside consultants, CROs, CMOs, research laboratories, and suppliers. Our direct external research and development expenses also include fees incurred under license and option agreements. We do not intend generally to allocate costs of certain management personnel, certain costs associated with our discovery efforts, certain supplies used in the laboratory, and certain facilities costs, including depreciation or other indirect costs, to specific programs when these costs are incurred across multiple programs and where it may not be practical to track them by program. We use internal resources along with outside parties primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities.
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally are expected to have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years if we commence additional manufacturing, continue planned clinical trials for TTX-MC138, or conduct other preclinical and clinical development, including submitting regulatory filings. In addition, we expect our discovery research efforts and related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with share-based compensation, will increase significantly over prior levels. Also, we may incur additional expenses related to milestone and royalty payments to third-parties with whom we have entered or may enter into license, acquisition and option agreements to assess, use or acquire intellectual property rights or rights to future product candidates.
In September 2021, we signed a statement of work with a European CMO to manufacture TTX-MC138 in accordance with current good manufacturing practices, or cGMP. Separately, we engaged a consulting toxicologist to assist us in designing and conducting IND-enabling studies including toxicology and pharmacokinetic, or PK, studies. These studies are designed to examine multiple parameters with a range of analytical assessments in support of regulatory submissions using radiolabeled or non-radiolabeled test substances. Toxicokinetic assessments can be conducted in parallel or concurrent with ongoing toxicology programs and in compliance with good laboratory practice, or GLP, requirements. We also engaged analytical testing laboratories to provide testing and other services, as well as documentation and reporting that meet regulatory requirements.
In late 2024, we and The University of Texas M. D. Anderson Cancer Center (“MD Anderson”) agreed to amend our five-year strategic collaboration agreement in favor of MD Anderson focusing solely on participation in our Phase I/II clinical trial. This amendment relieved us from the obligation to make up to $10 million of collaboration payments. We are obligated to pay charges incurred by MD Anderson in connection with clinical trial services. In January 2023, we made an initial payment of $250,000 to MD Anderson recorded as a Prepaid Expense pending such time as payments under the collaboration became due. Initial expenses of the clinical trial have been charged against the initial payment and for the nine months ended September 30, 2026 and 2025, were $23,800 and $146,372, respectively.
At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the manufacturing, preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows might commence from or related to any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain due to the numerous risks and uncertainties associated with product development and commercialization, including:
| Ø | the scope, progress, outcome and costs of our preclinical development activities, clinical trials, manufacturing activities, and other research and development; |
| Ø | the requirement to establish an appropriate safety and efficacy profile in IND-enabling studies; |
| Ø | the timing and terms of regulatory submissions and, if received, approvals to conduct clinical trials; |
| Ø | the number of sites and patients needed to complete clinical trials, the length of time required to enroll suitable patients and complete clinical trials, and the duration of patient follow-ups; |
33
Table of Contents
| Ø | assessment by us and regulatory agencies of data generated in clinical trials; |
| Ø | the timing, receipt and terms of marketing approvals, if any, from applicable regulatory authorities including the FDA and regulators outside the U.S.; |
| Ø | the extent of any post-marketing approval commitments that may be required of us by regulatory authorities; |
| Ø | establishing capabilities, or making arrangements with third-parties, to manufacture the quantities and quality of product we need to conduct pre-clinical studies, clinical trials and manufacturing validation activities in advance of any New Drug Applications that we may submit; |
| Ø | development and timely delivery of clinical-grade and commercial-grade drug formulations as required for use in our clinical trials and for manufacturing validation and regulatory agency review in connection with pursuit, if any, we may undertake for commercial launch of therapeutic candidates that receive marketing approval; |
| Ø | obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; |
| Ø | significant and changing government regulation; |
| Ø | launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; |
| Ø | competitive developments; and |
| Ø | maintaining an acceptable safety profile of our product candidates following approval, if any. |
Any changes in or adverse outcome of any of these variables or others with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of our product candidates.
SEPA financing issuance costs
SEPA financing issuance costs consist of the commitment fee and the legal, placement agent and other costs incurred in connection with the SEPA and the Convertible Notes. Because we have elected to account for the Convertible Notes at fair value, these costs are recognized in earnings as incurred.
Impairment of in-process research and development
Impairment of in-process research and development consists of charges to reduce the carrying amount of IPR&D assets acquired in business combinations to their estimated fair value when they are determined to be impaired. Acquired IPR&D is tested for impairment annually and whenever events or changes in circumstances indicate that it may be impaired.
General and administrative expenses
General and administrative expenses consist primarily of staffing costs comprising mainly salaries, benefits, and share-based compensation expense for personnel serving in executive, finance, and other business functions; professional fees for legal, patent, consulting, investor and public relations, accounting, tax and audit services; insurance costs, especially directors and officers liability insurance; corporate and office expenses, including facilities costs; and information technology costs.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our R&D activities, prepare for potential commercial activities including possible partnerships for the development or marketing of approved product candidates, if any, and the increased requirements of a larger and publicly-traded company. We also anticipate that we will incur significantly increased accounting, audit, tax, legal, regulatory, compliance and director and officer liability insurance costs as well as investor and public relations expenses associated with operating as a public company. Additionally, if and when we believe regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other personnel-related
34
Table of Contents
expenses involved in preparing for commercial operations, especially as it relates to the sales and marketing of that product candidate. There is a risk that we could incur the foregoing expenses but not receive the anticipated regulatory approval.
In September 2021, we engaged an independent compensation advisory firm to advise our Board’s Compensation Committee with respect to our compensation programs and governance model for officers, directors and employees. Our goal is to ensure that our culture, values, and strategic priorities are effectively represented in our compensation philosophy and strategy.
Other income (expense)
Change in fair value of warrant liabilities.
Our Series C Warrants, issued in the December 2024 private placement, do not meet the criteria for equity classification and are recorded as a liability remeasured to fair value each reporting period, with changes recognized in other income (expense).
Change in fair value of contingent consideration.
As part of the consideration for the Acquisition, we are obligated to pay up to $95.0 million upon the achievement of four development and regulatory milestones for Seviprotimut-L. The liability is remeasured to fair value each reporting period using a discounted cash flow analysis, and changes resulting from the passage of time, changes in discount rates and changes in the estimated probability and timing of the milestones are recognized in other income (expense).
Change in fair value of convertible note payable
Due to certain embedded provisions contained in the convertible notes that required bifurcation as derivative instruments, we elected to carry the convertible notes at their estimated fair value at issuance and remeasure the estimated fair value through earnings until settled.
Other
Other income (expense) also includes foreign currency transaction gains and losses on Euro-denominated vendor billings, interest income on cash balances and, in the 2025 periods, interest expense on our directors and officers insurance financing.
35
Table of Contents
Results of operations
The following table summarizes the approximate amounts of our consolidated results of operations for the periods indicated:
| | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, | | ||||||||||||||
| | 2026 | | 2025 | | Change | | 2026 | | 2025 | | Change | | ||||||
| | (in thousands) | | ||||||||||||||||
Operating expenses | | | | | | | | | | | | | | | | | | | |
Research and development | | $ | 3,548 | | $ | 3,161 | | $ | 387 | | $ | 12,349 | | $ | 7,947 | | $ | 4,402 | |
Acquired in-process research and development expense | | | — | | | — | | | — | | | 10,426 | | | — | | | 10,426 | |
General and administrative | | | 3,758 | | | 1,400 | | | 2,358 | | | 8,516 | | | 4,007 | | | 4,509 | |
SEPA financing issuance costs | | | 380 | | | — | | | 380 | | | 939 | | | — | | | 939 | |
Impairment of in-process research and development | | | 102,000 | | | — | | | 102,000 | | | 102,000 | | | — | | | 102,000 | |
Total operating expenses | | | 109,686 | | | 4,561 | | | 105,125 | | | 134,230 | | | 11,954 | | | 122,276 | |
Operating loss | | | (109,686) | | | (4,561) | | | (105,125) | | | (134,230) | | | (11,954) | | | (122,276) | |
| | | | | | | | | | | | | | | | | | | |
Other income (expense) | | | | | | | | | | | | | | | | | | | |
Change in fair value of warrant liabilities | | | 241 | | | (279) | | | 520 | | | 345 | | | (9,676) | | | 10,021 | |
Change in fair value of contingent consideration | | | 1,062 | | | — | | | 1,062 | | | 961 | | | — | | | 961 | |
Change in fair value of convertible note payable | | | 602 | | | — | | | 602 | | | 593 | | | — | | | 593 | |
Grant income | | | 64 | | | 22 | | | 42 | | | 225 | | | 524 | | | (299) | |
Currency exchange loss | | | (24) | | | (32) | | | 8 | | | (81) | | | (107) | | | 26 | |
Interest income | | | 43 | | | — | | | 43 | | | 187 | | | — | | | 187 | |
Interest expense | | | (7) | | | (6) | | | (1) | | | (7) | | | (6) | | | (1) | |
Total other income (expense) | | | 1,981 | | | (295) | | | 2,276 | | | 2,222 | | | (9,264) | | | 11,486 | |
Loss before income tax provision | | | (107,705) | | | (4,856) | | | (102,849) | | | (132,008) | | | (21,218) | | | (110,790) | |
Deferred income tax provision | | | 323 | | | — | | | 323 | | | 91 | | | — | | | 91 | |
Net loss | | | (107,382) | | | (4,856) | | | (102,526) | | | (131,917) | | | (21,218) | | | (110,699) | |
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | | | — | | | — | | | — | | | (1,840) | | | — | | | (1,840) | |
Net loss attributable to common stockholders | | $ | (107,382) | | $ | (4,856) | | $ | (102,526) | | $ | (133,758) | | $ | (21,218) | | $ | (112,540) | |
Comparison of the three and nine months ended September 30, 2026 and 2025
Research and development expenses
Research and development expenses increased $0.4 million and $4.4 million, respectively, in the three and nine months ended September 30, 2026, compared to the same periods in 2025. The change was primarily driven by increases in clinical trial spending, costs of production of drug used in the clinical trial, and intellectual property expenses, offset in part by reductions in certain preclinical testing and reduced lab facilities costs. In addition, in the nine months ended September 30, 2026, we incurred a one-time non-cash R&D charge with respect to the Unleash license shown as “Acquired in-process research and development expense” in the table above.
General and administrative expenses
General and administrative expenses increased $2.4 million and $4.5 million, respectively, in the three and nine months ended September 30, 2026, compared to the same periods in 2025. The three-month increase was driven primarily by $1.6 million of costs related to the separation of our former Chief Financial Officer and a $0.3 million loss on the settlement of the Wheeler litigation (see Note 11 to the condensed consolidated financial statements). The nine-month increase also reflects higher professional fees, primarily financial advisory, legal and accounting services related to the Acquisition and the Unleash license. These increases were offset in part by decreased spending for directors and officers liability insurance, investor relations services, and facilities expenses.
36
Table of Contents
SEPA financing issuance costs
SEPA financing issuance costs were $0.4 million and $0.9 million in the three and nine months ended September 30, 2026, respectively. The three-month amount consisted of placement agent fees on the Second Convertible Note. The nine-month amount consisted of placement agent fees of $0.5 million, the $0.3 million commitment fee settled in shares of Common Stock and legal fees of $0.2 million. Because we elected to record the Convertible Notes at fair value, these costs are expensed as incurred rather than deferred. There were no comparable costs in the 2025 periods.
Impairment of in-process research and development and goodwill
During the three months ended September 30, 2026, we recorded a non-cash impairment charge of $102.0 million related to the Seviprotimut-L IPR&D asset acquired in the Acquisition, reducing its carrying amount to its estimated fair value of $12.3 million. The sustained decline in our stock price and market capitalization, together with our limited available funding to advance Seviprotimut-L, indicated that the asset and goodwill should be tested for impairment. The decline in fair value primarily reflects a higher discount rate, reflecting the increased risk associated with our financial condition and market conditions since the Acquisition. Our goodwill impairment test indicated that the estimated fair value of our reporting unit exceeded its carrying amount, and no goodwill impairment was recorded. There were no comparable charges in the 2025 periods. See Note 3 to the condensed consolidated financial statements.
Change in fair value of warrant liability
We recognized non-cash gains from the change in fair value of our warrant liability of $241 thousand and $0.3 million in the three and nine months ended September 30, 2026, respectively, compared to non-cash losses of $0.3 million and $9.7 million in the same periods of 2025. The 2026 gains reflect the decrease in their fair value due to a decline in the Company’s stock price. The 2025 loss resulted primarily from the increase in the fair value of the Series D Warrants before their exchange for Common Stock in the first quarter of 2025.
Change in fair value of contingent consideration
The fair value of the contingent consideration payable to DEFJ decreased $1.1 million during the three months ended September 30, 2026 and $1.0 million during the nine months then ended primarily as a result of an increase in the related discount rate. Contingent consideration arose in connection with the Acquisition; there was no contingent consideration in the 2025 periods.
Change in fair value of convertible note payable
The change in fair value of convertible note payable resulted in a non-cash gain of $602 thousand and $593 thousand during the three and nine months ended September 30, 2026, respectively, driven primarily by the decline in our stock price. The convertible notes were initially issued during 2026, so there is no corresponding change in the 2025 periods.
Grant income
Grant income was $64 thousand and $22 thousand in the three months ended September 30, 2026 and 2025, respectively, and $0.2 million and $0.5 million in the nine months then ended. The nine-month decrease reflects the completion of most of the work funded by the 2024 SBIR Award during 2025. The third-quarter increase reflects the timing of eligible clinical trial costs.
Currency exchange gain (loss)
The currency exchange loss decreased during the three and nine months ended September 30, 2026, compared to the same periods in 2025, as a result of fluctuations in the foreign exchange rate.
Interest income
Interest income increased $43 thousand and $0.2 million, respectively, in the three and nine months ended September 30, 2026, compared to the same periods in 2025 reflecting income on higher cash balances as a result of debt and equity financings during 2026.
37
Table of Contents
Cash flows
The following table summarizes the approximate amounts of consolidated our cash flows for the periods indicated:
| | | | | | | |
| | Nine months ended September 30, | | ||||
| | 2026 | | 2025 | | ||
Net cash used in operating activities | | $ | (18,042,782) | | $ | (11,374,219) | |
Net cash provided by financing activities | | | 4,865,100 | | | 8,399,071 | |
Net change in cash | | $ | (13,177,682) | | $ | (2,975,148) | |
Comparison of the nine months ended September 30, 2026 and 2025
Operating activities
Net cash used in operating activities was $18.0 million in the nine months ended September 30, 2026 compared to $11.4 million in the same period in 2025. The 2026 amount reflects our net loss of $131.9 million, adjusted for $111.4 million of net non-cash items, primarily the $102.0 million impairment of in-process research and development, the $10.4 million acquired in-process research and development charge for the Unleash program, the $0.3 million loss on the Wheeler litigation settlement, the $0.3 million SEPA commitment fee settled in shares of Common Stock, $0.3 million of share-based compensation expense, partially offset by the $0.1 million deferred income tax benefit and non-cash gains of $1.0 million from the change in fair value of contingent consideration and $0.3 million from the change in fair value of warrant liabilities and $0.6 million from the change in fair value of convertible notes payable; and for $2.5 million of cash provided by changes in operating assets and liabilities, principally the $2.3 million collection of the reimbursement right from DEFJ, the $1.0 million collection of the grant receivable and a $0.4 million increase in accounts payable and accrued expenses, partially offset by a $1.1 million increase in prepaid expenses.
The $6.7 million increase in cash used in operating activities compared to 2025 reflects the higher level of clinical trial, manufacturing and administrative spending, including the costs of the Polynoma programs acquired in October 2025. Cash used in operating activities in the 2025 period reflected our net loss of $21.2 million adjusted primarily for the $9.7 million non-cash loss on warrant liabilities and $0.4 million of share-based compensation expense.
Financing activities
Net cash provided by financing activities of $4.9 million in the nine months ended September 30, 2026, consisted of $5.7 million of net proceeds from the First and Second Convertible Notes issued in April and July 2026, partially offset by the $0.8 million repayment of Convertible Note principal, including the related prepayment premium, in September 2026. In the 2025 period, we received $8.9 million of net proceeds from the March 2025 public offering of common stock and warrants, partially offset by $0.5 million of offering costs paid during the period.
Liquidity and capital resources
Sources of liquidity
Since inception, we have not generated any revenue from product sales or any other sources, and we have incurred significant consolidated operating losses and negative consolidated cash flows from operations. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if ever. We have funded our operations to date primarily with proceeds from our IPO and other equity financings, SBIR Awards, and funds from borrowings under convertible promissory notes. As of September 30, 2026, we had cash of approximately $4.6 million.
In April and July 2026, we issued Convertible Notes to Yorkville under the SEPA with an aggregate principal amount of $6.0 million, for net proceeds of $5.7 million after a 5% purchase price discount. The Convertible Notes bear interest at 5% per year and mature 18 months after issuance, subject to extension. Yorkville may convert the notes into Common Stock at any time, and any amount outstanding at maturity converts automatically. During the nine months ended September 30, 2026, Yorkville converted $1.1 million of principal, plus accrued interest, into 417,095 shares of Common Stock. If our daily VWAP is below the $1.72 Floor Price
38
Table of Contents
for five trading days during any seven consecutive trading days, we must make monthly cash payments of 18% of the outstanding principal, plus a 10% premium and accrued interest, until the notes are repaid or our VWAP exceeds the Floor Price for ten consecutive trading days. This condition was met in September 2026. In September 2026, we prepaid $0.8 million in exchange for a waiver through October 31, 2026, leaving approximately $4.1 million of principal outstanding. The Company’s daily VWAP has remained below the Floor Price since October 31, 2026, and the Company has been in discussions with Yorkville regarding the Convertible Notes (see Note 8 and Note 18 to our condensed consolidated financial statements).
In connection with the SEPA, we also have the right to sell to Yorkville up to $14.0 million of shares of our Common Stock, subject to certain limitations and conditions set forth in the SEPA. If more than 10% of the original aggregate balance of the Convertible Notes remains outstanding, we will not be able to require Yorkville to purchase our shares of Common Stock pursuant to the SEPA except in limited circumstances including where an Amortization Event has occurred and our obligation to make monthly prepayments under the Promissory Note has not ceased. Sales of shares of Common Stock to Yorkville and the timing of any such sales, if we elect to sell shares of Common Stock to Yorkville at a future date, are at our option, and we are under no obligation to sell any shares of Common Stock to Yorkville. As consideration for Yorkville’s commitment under the SEPA, we agreed to pay to Yorkville a commitment fee equal to 2.0% of the Commitment Amount, or $0.3 million, which we paid in shares of Common Stock. As of the date of this Quarterly Report on Form 10-Q, no shares had been sold under the SEPA.
Future requirements
We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we advance preclinical activities and pursue additional clinical trials of TTX-MC138. We expect to incur additional costs associated with operating as a public company, including significant legal, accounting, tax, investor relations and other expenses.
The timing and amount of our operating expenditures will depend largely on our ability to, among other things:
| Ø | advance clinical development of TTX-MC138 and clinical or preclinical development of other drug candidates; |
| Ø | develop validated processes to effectively manufacture, or have manufactured on our behalf, our preclinical and clinical drug materials and for commercial manufacturing of any product candidates that may receive regulatory approval; |
| Ø | seek regulatory approvals for any product candidates that successfully complete clinical trials; |
| Ø | establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we obtain marketing approval and intend to commercialize on our own; |
| Ø | establish collaborations to commercialize any product candidates for which we obtain marketing approval but do not intend to commercialize on our own; |
| Ø | expand our operational, financial and management systems and hire additional personnel, including personnel to support our clinical development, quality control, scientific research, manufacturing and commercialization efforts, our general and administrative activities and our operations as a public company; and |
| Ø | obtain or develop new intellectual property and maintain, expand and protect our intellectual property portfolio. |
We believe that our current cash will be sufficient to support our operating expenses and capital expenditure requirements into the first quarter of 2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Changed circumstances may also result in the depletion of our capital resources more rapidly than we currently anticipate. We anticipate that we will require additional capital for continued research, development, and clinical trial costs as we continue to conduct activities related to seeking regulatory approval of our product candidates, for operations, and for licenses or acquisitions of other product candidates we may choose to pursue. If we receive regulatory approval for TTX-MC138 or other product candidates we may develop, we expect to incur significant commercialization expenses related to product
39
Table of Contents
manufacturing, sales, marketing and distribution, all of which will vary depending on where and how we choose to commercialize approved product candidates.
Because of the numerous risks and uncertainties associated with research, development and commercialization of biologic product candidates, we are unable to estimate the exact amount and timing of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
| Ø | the scope, progress, outcome and costs of conducting preclinical development activities, clinical trials, and other research and development; |
| Ø | the costs, timing and outcome of regulatory review of our product candidates; |
| Ø | the costs, timing and requirements to manufacture our product candidates for our preclinical development efforts and our clinical trials; |
| Ø | the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; |
| Ø | the costs of manufacturing commercial-grade product meeting quality and regulatory requirements and building inventory of such product to support commercial activities; |
| Ø | the ability to receive non-dilutive funding, including grants from governments, organizations and foundations; |
| Ø | the revenue, if any, received from commercial sales of our products, should any of our product candidates receive marketing approval; |
| Ø | the costs of preparing, filing and prosecuting patent applications, maintaining, expanding and enforcing our intellectual property rights, and defending intellectual property-related claims; |
| Ø | the terms of any industry collaborations we may be able to establish; |
| Ø | the extent to which we acquire or license other product candidates and technologies; and |
| Ø | the efficiency with which we operate our business. |
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, governmental funding, collaborations, strategic partnerships and alliances, and marketing, distribution or licensing arrangements with third parties. There is no assurance that funding from any of the foregoing sources or otherwise will be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests in our common stock may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, we could incur fixed payment obligations as a result of any debt or preferred equity financing.
If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances, or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue or earnings streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.
If we are unable to raise additional funds when needed, we will likely need to consider cost reduction strategies which may include, among others, amending, delaying, limiting, reducing, or terminating our development programs, and we may need to seek an in-court or out-of-court restructuring of our liabilities. In the event of such future restructuring activities, holders of our common stock and other securities will likely suffer a total loss of their investment.
40
Table of Contents
Contractual obligations and commitments
At September 30, 2026, we had no future minimum lease payments under non-cancelable operating lease commitments. From time to time, we enter into contracts in the normal course of business with CROs, collaborators, CMOs and other third-parties for the manufacture of our product candidates, to support clinical trials and preclinical research studies and testing, and for other purposes. Any payments due upon completion or cancellation of these contracts generally consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation although some agreements provide for termination fees or payments for the balance of the term of the agreement.
Collaboration obligations
We recently launched a Phase 2a clinical trial to evaluate TTX-MC138 in patients with ct-DNA positive colorectal cancer with Minimal Residual Disease (MRD), a setting characterized by significant unmet need with the potential to intervene before metastatic recurrence. The Phase 2a trial is being conducted in collaboration with Quantum Leap Health Care Collaborative (“Quantum Leap”) as part of its PRE-I-SPY clinical trial platform. The PRE-I-SPY program incorporates TTX-MC138 into a clinical trial designed as a multicenter, open-label, one-year treatment duration with one year follow up. The trial will evaluate event-free survival, ctDNA dynamics and pharmacokinetics of TTX-MC138 in up to 45 patients who (i) have stage I-III adenocarcinoma of the colon or rectum and are ctDNA positive with minimal residual disease detected by tumor-informed ctDNA assays, (ii) have completed standard curative-intent therapy, and (iii) show no radiographic evidence of recurrence or metastasis. This trial was initiated in the second quarter 2026 with initial patient enrollments expected in the first half of 2027. The revised timing reflects delays due to the collaboration and refocused efforts on recruitment Dr. Paula Pohlmann of the MD Anderson Cancer Center is the Principal Investigator. The study is being conducted under a Quantum Leap IND and cross-referenced to our IND. The total amount of the Quantum Leap agreement is approximately $7.3 million payable against milestones tied to Quantum Leap’s performance under the terms of the collaboration agreement.
On July 29, 2022, we signed a five-year strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center (“MD Anderson”). Under the collaboration, we anticipated making certain expenditures with respect to Phase I and Phase II clinical trials in part through MD Anderson as a clinical site. MD Anderson was also expected to provide preclinical work under the collaboration. The details of clinical and preclinical work were to be mutually agreed by the parties prior to commencing work. We had agreed to fund up to $10.0 million over the term of the collaboration. In January 2023, we made an initial payment of $0.3 million to MD Anderson recorded as a Prepaid Expense pending such time as payments under the collaboration became due. As a result of changes at both organizations, we and MD Anderson agreed to amend the collaboration in favor of MD Anderson focusing solely on participation in our Phase I/II clinical trial. This amendment relieved us from the obligation to make up to $10.0 million of collaboration payments. Initial expenses of the clinical trial were charged against the initial payment made to MD Anderson. For the nine months ended September 30, 2026 and 2025, MD Anderson expenses were $23,800 and $146,372, respectively.
Critical accounting policies and significant judgments and estimates
We have based our management’s discussion and analysis of consolidated financial condition and consolidated results of operations on our consolidated financial statements. Our consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for our judgments about the carrying values of assets and liabilities that are not readily apparent from other sources including contingent consideration. We evaluate estimates and assumptions on an ongoing basis. Our actual consolidated results may differ from amounts derived from these estimates or from amounts obtained under different assumptions or conditions.
While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements presented elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.
41
Table of Contents
Indefinite-lived intangible assets
Indefinite-lived intangible assets consist of In-Process Research and Development (“IPR&D”). The fair values of IPR&D project assets acquired in business combinations are capitalized. We generally utilize the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, the estimated probability of regulatory success rates, anticipated patent protection, expected pricing, expected treated population, and estimated payments (e.g., royalties). The estimated future net cash flows are then discounted to the present value using a discount rate that we believe is appropriate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate.
Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. We consider many factors in evaluating whether the value of our intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, outlook and market performance of our industry and recent and forecasted financial performance.
During the three months ended September 30, 2026, we recorded a $102.0 million impairment of the Seviprotimut-L IPR&D asset. Its estimated fair value of $12.3 million is most sensitive to the discount rate (19.0%), the probability of regulatory approval (39.5%) and the expected timing of development and commercialization, which depends on our ability to fund the program. The decline from the acquisition-date fair value primarily reflects the higher discount rate, which reflects the increased risk associated with our financial condition, including the sustained decline in our stock price and market capitalization, and market conditions since the Acquisition. Our goodwill impairment test estimated the fair value of our reporting unit at approximately $122.3 million using a discounted cash flow analysis at a 19.0% discount rate. A one percentage point increase in the discount rate would have reduced that estimate to approximately $74 million, which would still have exceeded the carrying amount of the reporting unit.
Research and development expenses
In preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses.
We rely to a significant extent on third-parties to conduct preclinical studies, manufacture drug substance and drug products, provide materials, conduct analytical testing and to provide clinical trial services, including trial conduct, data management, statistical analysis, medical and safety monitoring, and electronic compilation. At the end of each reporting period, we compare payments made to each service provider and clinical trial site to the estimated progress towards completion of the related project. Factors that we consider in preparing these estimates include materials delivered or services provided, milestones achieved, the number of patients enrolled in studies, and other criteria related to the efforts of these vendors. These estimates are subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, we record net prepaid or accrued expenses related to these costs.
The estimating process involves reviewing open contracts and purchase orders, communicating with our relevant personnel to identify services that have been performed on our behalf or deliveries of materials made to us, and estimating the level of service performed and the associated cost incurred for those services when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. As of each balance sheet date, we make estimates of our accrued expenses based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:
| Ø | vendors, including research laboratories, in connection with preclinical development activities; |
42
Table of Contents
| Ø | CROs and investigative sites in connection with preclinical testing and clinical trials; |
| Ø | CMOs in connection with the production of drug substance and drug product formulations for use in preclinical testing and clinical trials; and |
| Ø | clinical trial sites. |
The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors exceed the level of services provided at a particular time, resulting in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.
Warrant accounting
We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”), and ASC 815 “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares and whether warrant holders could potentially require “net cash settlement” in a circumstance outside of our control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end-date while the warrants are outstanding.
For issued or modified warrants that meet all the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and at their fair value on each balance sheet date thereafter. Changes in the estimated fair value of warrants classified as liabilities are recognized as a non-cash gain or loss on our statements of operations.
Warrants we issued upon our financings in January and July 2024 and in March 2025 met the criteria for equity classification under ASC 815 and were classified as equity. Warrants we issued upon a financing that closed December 2, 2024, did not meet the criteria for equity classification under ASC 815 and were classified as liabilities. Warrants issued upon our financings in 2023 met the criteria for equity classification under ASC 815 and were classified as equity.
Contingent Consideration
In connection with the Acquisition, we agreed to make up to $95.0 million in contingent milestone payments (each, a “Milestone Payment” and collectively, the “Milestone Payments”) (the “Acquisition Obligation”) to DEFJ upon the achievement within ten (10) years of the date of the MIPA of the following milestone events (each, a “Milestone Event”) upon the first achievement by us or on our behalf (including by any licensee or assignee of rights to commercialize the Seller Lead Candidate as defined in the MIPA) of the corresponding Milestone Event as follows: (i) a milestone payment of five million U.S. dollars ($5.0 million) upon the first dosing of the Seller Lead Candidate in a patient in a United States Phase 3 Clinical Study; (ii) a milestone payment of ten million U.S. dollars ($10.0 million) upon the achievement of the applicable primary endpoint in a United States Phase 3 Clinical Study of the Seller Lead Candidate; (iii) a milestone payment of twenty million U.S. dollars ($20.0 million) upon the first submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for the Seller Lead Candidate; and (iv) a milestone payment of sixty million U.S. dollars ($60.0 million) upon the first approval by the FDA of a BLA for the Seller Lead Candidate.
The estimated fair value of the Acquisition Obligation at September 30, 2026, and at December 31, 2025, was approximately $5.4 million and $6.4 million, respectively.
43
Table of Contents
Fair Value Option
The Company has elected the fair value option for the Convertible Notes associated with the SEPA which are recorded in Notes payable – convertible, at fair value on the Company’s Consolidated Balance Sheets. The Company’s fair value option elections are made in accordance with the guidance in Accounting Standards Codification (“ASC”) 825, Financial Instruments, allowing entities to make an irrevocable election of fair value as the initial and subsequent measurement attributed for certain eligible financial assets and liabilities. The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an
entire instrument. Assets and liabilities measured at fair value pursuant to this guidance are required to be reported on the Company’s Consolidated Balance Sheets separate from instruments using another accounting method.
Because we have elected the fair value option for the Convertible Notes, the costs and fees incurred in connection with the SEPA and the Convertible Notes are recognized in earnings as incurred and presented as SEPA financing issuance costs in our condensed consolidated statements of operations, and changes in the fair value of the Convertible Notes, including the component attributable to accrued interest, are recognized in other income (expense) in the period they occur.
Factors that may affect future results
You should refer to “Risk Factors” elsewhere in this Quarterly Report on Form 10-Q for a discussion of important factors that may affect our future results.
Off-balance sheet arrangements
During the periods presented, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
Recently issued accounting pronouncements
A description of recently issued accounting pronouncements that may affect our consolidated financial position and consolidated results of operations is disclosed in Note 2 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Internal control over financial reporting
We previously determined that material weaknesses in our internal control over financial reporting existed prior to our IPO. See “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, or our 2025 Annual Report, under the caption, “We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our consolidated financial condition or consolidated results of operations, which may adversely affect our business.” We subsequently retained an independent consulting firm to assist us in improving our control systems and procedures, and have implemented new software systems designed to enhance our ability to process financial transaction information. There is no assurance that any controls we implement will prevent fraud or enable accurate or timely financial reporting. In assessing our financial controls and procedures as described in “Item 4. Controls and Procedures,” our management determined that our internal control resulted in a material weakness as of December 31, 2025, related to certain transactions arising from the Acquisition. Based on this assessment, our management concluded that while we believe that all significant and unusual transactions have been appropriately recorded and that our consolidated financial statements at and for the nine months ended September 30, 2026, are fairly presented in all material respects in accordance with U.S. GAAP, the material weakness reported in our 2025 Annual Report still exists because the changes we have made to our controls must operate for at least six months and be tested before we can conclude that our internal control over financial reporting is effective and the material weakness has been fully remediated. Management will conduct a more complete assessment of the effectiveness of our internal controls in connection with our 2026 year end audit.
44
Table of Contents
Emerging Growth Company and Smaller Reporting Company Status
We are an “emerging growth company” as defined in the JOBS Act. We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; (ii) the date we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (iv) December 31, 2026, which is the last day of the fiscal year ending after the fifth anniversary of our initial public offering.
In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards by delaying adoption of these standards until they would apply to private companies. We have elected to use the extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date on which we (i) are no longer an emerging growth company and (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of effective dates applicable to public companies.
We are also a “smaller reporting company” meaning that the market value of our stock held by non-affiliates plus the aggregate amount of gross proceeds to us as a result of our initial public offering is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We will continue to be a smaller reporting company until either (i) the market value of our stock held by non-affiliates is more than $250 million or (ii) our annual revenue is greater than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is greater than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Information Technology Risks
Our data and computer systems are subject to threats from malicious software codes and viruses, phishing, ransomware, business email compromise attacks, or other cyber-attacks. In the past, we have been subject to what we believe was a phishing attack. We do not believe this incident had a material impact on our business or consolidated financial condition. However, the number and complexity of these threats continue to increase. See “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, under the caption, “We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.” We have taken and continue to take steps to mitigate the risk of cyberattacks including enhancing email screening, engaging with a computer support firm to provide forensics and training services, among other services, and enhancing security protocols for vendor payments. We intend to take additional steps to continue to enhance cybersecurity defenses. Despite steps we have taken or may take in the future, there is no assurance that we will not suffer material and adverse consequences as a result of cyberattacks or other computer-based activities. In addition, there is no assurance that any steps we may take will be effective or prevent material adverse effects on our consolidated financial condition or consolidated results of operations.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest rate risk
We are exposed to market risk related to changes in interest rates. As of September 30, 2026, and December 31, 2025, our cash was held in checking and savings accounts at major U.S. banks. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of our holdings, an immediate 10% change in the interest rate would not materially affect the fair market value of our investments or our consolidated financial position or consolidated results of operations.
As of September 30, 2026, we had two convertible notes outstanding, each of which bears a fixed interest rate; we therefore do not believe we are subject to interest rate risk related to debt. At December 31, 2025, we had no debt outstanding.
45
Table of Contents
Foreign currency exchange risk
Our primary exposure to market risk is foreign exchange rate sensitivity to the Euro, the currency for certain of our major purchases. Foreign currency transaction gains or losses, if any, are recorded as a component of other income (expense) in our consolidated statements of operations. For the three and nine months ended September 30, 2026, we recognized losses on foreign currency transactions of approximately $24 thousand and $81 thousand, respectively. An immediate 5% change in the Euro exchange rate would not have a material effect on our consolidated results of operations.
As we continue to develop our business, our consolidated results of operations and consolidated cash flows will likely be more affected by fluctuations in foreign currency exchange rates, including the Euro and other currencies, which could adversely affect our consolidated results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign currency exchange risk.
ITEM 4. CONTROLS AND PROCEDURES.
Disclosure Controls and Procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a–15(f) or 15d-15(f). Our internal control system was designed to provide reasonable assurance to our management and our Board regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Our management, with the participation of our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of September 30, 2026. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of that date, our disclosure controls and procedures were not effective because of the material weakness in our internal control over financial reporting previously reported in our Annual Report on Form 10-K for the year ended December 31, 2025, which has not been remediated as of September 30, 2026. Notwithstanding this material weakness, our management concluded that our consolidated financial statements for the nine months ended September 30, 2026 fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in accordance with U.S. GAAP.
Remediation Efforts
The material weakness will not be considered remediated until the enhanced controls have operated for a sufficient period of time and management has concluded, through testing, that they are operating effectively. To address identified internal control deficiencies, including the material weakness reported in our 2025 Annual Report, we took steps such as implementing more robust accounting policies and procedures, implementing new accounting software, and, most particularly, hiring of or engaging additional finance and accounting personnel including consultants and other third-party resources with requisite experience and technical accounting
46
Table of Contents
expertise. The small size of our finance and accounting staff requires us to rely on outside parties for certain accounting analyses such as for non-routine transactions. We also engaged an independent consulting firm to assist us in evaluating and improving our accounting processes, and in evaluating new accounting policies. Our independent consulting firm will conduct further testing and assessments of our controls related to the material weakness and overall. Management will conduct a more complete assessment of the effectiveness of our internal controls in connection with our 2026 year end audit.
We believe that these efforts have improved our internal control over financial reporting. However, implementation of these and other measures will be ongoing and will require validation and testing of their design and operating effectiveness over a sustained period of financial reporting cycles. We cannot reasonably estimate when these remediation measures will be completed nor can we assure you that the measures we have taken to date, and are continuing to take, will be sufficient to preclude potential future material weaknesses. Our management will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary.
Changes in Internal Control over Financial Reporting
Except as described under ‘Remediation Efforts’ above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Following the resignation of our Chief Financial Officer on September 9, 2026, our Interim Chief Financial Officer assumed responsibility for the review and approval controls over our financial close and reporting process, and we engaged additional third-party accounting advisory resources to support the financial close and the review of complex and non-routine transactions. The design of those controls did not change. The integration of ABCJ, LLC into our system of internal control over financial reporting continues and may result in future changes to our internal control environment.
47
Table of Contents
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
On April 24, 2026, Wheeler Bio, Inc. (“Wheeler”) filed a complaint in the Supreme Court of the State of New York, County of New York, captioned Wheeler Bio, Inc. v. Polynoma LLC, et al., No. 652458/2026 against Polynoma and us (the “Wheeler Action”). The Wheeler Action asserts two causes of action: breach of contract against Polynoma and intentional interference with contractual relations against us. The claims arise out of an agreement between Wheeler and Polynoma for certain contract development and manufacturing services offered by Wheeler (the “Wheeler Agreement”). Wheeler alleges that, on October 1, 2025, Polynoma terminated a Statement of Work and a Change Order effective immediately without advance notice required by the Wheeler Agreement, and has failed to pay certain delay fees, cancellation fees, and invoices generated in connection with the Wheeler Agreement. Wheeler further alleges that we caused Polynoma to terminate the Wheeler Agreement and to refuse to pay the fees at issue. The Wheeler Action sought various amounts for compensatory and punitive damages, restitution, pre- and post-judgment interest, and attorneys’ fees and costs involving as much as approximately $9.2 million. The Company disputed the claims in the Wheeler Action. Under the Wheeler Agreement, the parties agreed that any disputes regarding Wheeler’s performance would be resolved by arbitration. The Company filed a motion to compel arbitration and to stay the litigation pending the outcome of arbitration. On July 30, 2026, the Court entered an order compelling the dispute to arbitration and staying the litigation pending a final decision in that arbitration. On November 6, 2026, the parties agreed to a resolution of the Wheeler Action, and on November 11, 2026, the parties filed a stipulation of discontinuance of the Wheeler Action with prejudice.
ITEM 1A. Risk Factors
Factors that could cause our actual results to differ materially from those in this Quarterly Report on Form 10-Q are any of the risks described in our Annual Report on Form 10-K for the year ended December 31, 2025, or our Annual Report, filed with the SEC, as amended and supplemented by the information in our subsequent Quarterly Reports on Form 10-Q or other subsequent filings, together with all of the other information contained in this Quarterly Report, including our unaudited consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report, and the risk factors set forth below. The risk factors disclosure in our Annual Report and subsequent Quarterly Reports on Form 10-Q is qualified by the information that is described in this Quarterly Report. Any of these factors could result in a significant or material adverse effect on our business, consolidated results of operations or consolidated financial condition. Additional risk factors not currently known to us or that we currently deem immaterial may also have a material adverse effect on our business, consolidated financial condition or consolidated results of operations. You should review the risk factors in our Annual Report, subsequent SEC filings and the risk factors discussed below for important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
Any financial or strategic option we pursue may not be successful.
In October 2026, we announced the initiation of a formal strategic process to evaluate opportunities designed to maximize the value of our company and oncology portfolio, including our lead product candidate, TTX-MC138. Such opportunities include, but are not limited to, a merger, acquisition, business combination, or other strategic transactions involving us or our assets. The process of evaluating these strategic options may be costly, take more time than anticipated, present time-consuming and complex issues and we may incur significant costs related to this ongoing evaluation, such as legal, accounting and advisory fees and expenses and other related charges. The strategic process may also divert the attention of our management and board of directors from the day-to-day operation of our business, and uncertainty about the outcome of the process may make it more difficult to retain and motivate key employees and other personnel, the loss of whom could harm our business and our ability to complete any strategic transaction. There can be no assurance of identification, let alone, completion of any particular course of action or a defined timeline for completion, and
48
Table of Contents
we can provide no assurance that any strategic alternative we identify or pursue will have a positive impact on our results of operations or financial condition.
Our outstanding Convertible Notes and conditional access to funding under the Yorkville SEPA could make us more vulnerable to downturns in our financial condition and declines in our stock price.
In April and July 2026, we issued Convertible Notes to Yorkville in an aggregate principal amount of $6.0 million in connection with the SEPA, receiving aggregate proceeds of $5.7 million after a 5% purchase price discount. At September 30, 2026, $4,141,000 of aggregate principal remained outstanding under the Convertible Notes. The Convertible Notes bear interest at 5% per year, increasing to 18% upon an event of default, and mature 18 months after their respective issuance dates, subject to extension. Although outstanding principal and accrued but unpaid interest generally convert into Common Stock at maturity, subject to satisfaction of the applicable Equity Conditions, we may be required to make substantial cash payments before maturity under the amortization provisions described below.
An Amortization Event occurs if the daily volume weighted average price, or VWAP, of our Common Stock is below the $1.72 Floor Price for five trading days during any period of seven consecutive trading days. Following an Amortization Event, monthly cash payments begin on the seventh trading day after the event. Each payment equals 18% of the outstanding principal as of the date of the Amortization Event (or the remaining principal, if less), plus a 10% premium on the principal paid and accrued interest. Payments continue until the Convertible Notes are repaid or the daily VWAP exceeds the Floor Price for ten consecutive trading days, unless a subsequent Amortization Event occurs. These conditions were met in September 2026. On September 30, 2026, we paid Yorkville $840,975, consisting of $759,000 of principal, a $75,900 premium and $6,075 of accrued interest, in exchange for a waiver of Amortization Events through October 31, 2026. If an Amortization Event occurs after that waiver period and no further relief is obtained, the resulting cash payments could materially reduce our available cash, shorten our cash runway and divert funds from development programs and other operating needs. The Company’s daily VWAP has remained below the Floor Price since October 31, 2026, and the Company has been in discussions with Yorkville regarding the Convertible Notes. Unless the event is waived, the Company is required to make the monthly cash payments in accordance with the terms of the Convertible Notes described in Note 8 to our condensed consolidated financial statements.
The SEPA also provides us with the right to sell up to $14.0 million of Common Stock to Yorkville, subject to its terms, limitations and conditions. As of the date of this Quarterly Report on Form 10-Q, no shares had been sold under the SEPA. This potential funding is not cash on hand, and we cannot assure you that we will be able to access it when needed or insufficient amounts. Actual sales depend on, among other things, satisfaction of the conditions to Yorkville’s purchase obligations, market conditions and the trading price of our Common Stock. Sales under the SEPA and conversions of the Convertible Notes would dilute existing stockholders and could put downward pressure on our stock price. Declines in our stock price could increase the number of shares issued, subject to the applicable conversion floor, and could trigger further cash payment obligations under the Convertible Notes. If we cannot meet these obligations or obtain additional financing on acceptable terms, we may need to refinance our obligations, dispose of assets, delay or scale back development programs, or reduce or cease operations, which could materially adversely affect our business and financial condition.
We could lose our listing on the Nasdaq Capital Market if our stockholders’ equity or the closing bid price of our common stock do not meet Nasdaq requirements, if we do not meet Nasdaq’s new requirement with respect to a Nasdaq-listed company’s market value of listed securities, or if we do not comply with other Nasdaq requirements. The loss of our Nasdaq listing would in all likelihood make our common stock significantly less liquid and adversely affect its value, including a total loss of value. Loss of our Nasdaq listing would in all likelihood also make it much more difficult for us to raise additional capital.
Our stockholders’ equity previously did not meet Nasdaq Capital Market, LLC, or Nasdaq, rules for continued listing of our stock on Nasdaq. As previously disclosed, on May 19, 2026, we received a deficiency notice to this effect from Nasdaq with the opportunity to present our plan to Nasdaq for regaining compliance. On July 15, 2026, Nasdaq approved our initial listing application which required $5.0 million of stockholder equity on the basis of the pro forma financial statements included in the proxy statement filed with the SEC on June 2, 2026, as subsequently amended on July 17, 2026. On July 20, 2026, we obtained stockholder approval for the conversion of our preferred stock and, between July 20, 2026, and August 10, 2026, all of our outstanding shares of preferred stock converted into Common Stock. As of September 30, we had stockholder equity of $32.1 million, which exceeds the minimum continued listing requirement of $2.5 million. Therefore, we believe we will be deemed to be in compliance with Nasdaq’s continued listing standards; however, there is no assurance that we will continue to meet Nasdaq rules for continued listing of our stock.
49
Table of Contents
On July 22, 2026, the SEC approved a new Nasdaq rule mandating immediate delisting of companies listed on Nasdaq if the market value of their listed securities, or MVLS, falls below $5 million for 30 consecutive business days. Nasdaq defines MVLS as the closing bid price of a company’s stock multiplied by its total listed shares outstanding. Under the new rule, there is no cure period and appealing to a Nasdaq Hearings Panel will not halt suspension of trading on Nasdaq. While the SEC issued a stay on July 29, 2026, pausing this rule, there is no assurance that the new rule will not become effective, that our MVLS will remain above $5 million for 30 consecutive business days or that our stock will not be delisted. As of November 12, 2026, based on our Nasdaq official closing price of $1.39 per share, our MVLS was approximately $24.1 million.
In the event of a delisting from Nasdaq, our stock would likely be traded in the over-the-counter inter-dealer quotation system, more commonly known as the OTC. OTC transactions involve risks in addition to those associated with transactions in securities traded on the securities exchanges, such as Nasdaq, or Exchange-listed stocks. Many OTC stocks trade less frequently and in smaller volumes than Exchange-listed stocks. Accordingly, our stock would be less liquid than it would be otherwise. Also, the prices of OTC stocks are often more volatile than Exchange-listed stocks. Additionally, many institutional investors are prohibited from investing in OTC stocks, and it might be more challenging to raise capital when needed. Further, a delisting of our stock from trading on Nasdaq could also adversely affect our reputation, relationships with business partners, and access to strategic opportunities.
As further described elsewhere in this Quarterly Report on Form 10-Q, in light of our financial position and our need to raise additional capital, delisting of our common stock from Nasdaq would materially limit our ability to obtain additional equity capital.
We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, scale back or discontinue some of our therapeutic candidate development programs or commercialization efforts.
The development of pharmaceutical drugs and biological products is capital intensive. At September 30, 2026, we had cash of approximately $4.6 million. We believe this will be sufficient to support our operating expenses and capital expenditure requirements into the first quarter of 2027. In September 2026, we made a cash prepayment of approximately $0.8 million under our Convertible Notes to obtain a waiver of the notes' amortization provisions through October 31, 2026. The Company’s daily VWAP has remained below the Floor Price since October 31, 2026, and the company has been in discussions with Yorkville regarding the Convertible Notes (see Note 8 and Note 18 to our condensed consolidated financial statements). If our stock price remains below the Floor Price after that date, we may be required to make monthly cash payments of approximately 20% of the outstanding principal, which would shorten our cash runway. As a result, we will need to raise additional capital to continue as a going concern. Unless we receive additional funding, we may not be able to complete clinical trials we begin. Further, we may only be able to complete the trial in a small subset of patients and in only one tumor type. Even if completed, we will require additional funds to advance further. If we are capital constrained, we may not be able to meet our obligations. If we are unable to meet our obligations, or we experience a disruption in our cash flows, it could limit or halt our ability to continue to develop our therapeutic candidates or even to continue operations, either of which occurrence would have a material adverse effect on us.
We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we continue the research and development of, advance the preclinical and clinical activities of, and seek marketing approval for, our current or future therapeutic candidates. In addition, if we obtain marketing approval for any of our current or future therapeutic candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution to the extent that such sales, marketing, product manufacturing and distribution do not become the responsibility of collaborators. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our current or future therapeutic candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we expect to continue to incur significant costs associated with operating as a public company. If we are unable to raise capital when needed, we would be forced to delay, scale back or discontinue the development and commercialization of one or more of our therapeutic candidates, delay our pursuit of potential licenses or acquisitions, or significantly reduce our operations.
50
Table of Contents
Identifying potential current or future therapeutic candidates, manufacturing, and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales. In addition, our current or future therapeutic candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to continue to rely on additional funding to achieve our business objectives. In addition to having obtained funding from sales of equity and equity-related securities, we have also received funding under grants awarded by U.S. federal government agencies and may seek additional grants in the future. Recently, an application we submitted to the National Cancer Institute was removed from consideration based on a foreign risk assessment. There can be no assurance that any future applications we submit to any U.S. federal government agencies will result in any awards, which could increase our need to obtain funding from other sources.
Because we are relying on the exemptions from corporate governance requirements as a result of being a “controlled company” within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.
Because entities affiliated with CKLS control a majority of our common stock, we are a “controlled company” within the meaning of the Nasdaq listing standards. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a “controlled company” and may elect not to comply with certain Nasdaq corporate governance requirements, including (1) the requirement that a majority of the Board consist of independent directors, (2) the requirement that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities, and (3) the requirement that the Board have a compensation committee composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities. However, our Board is currently comprised of a majority of independent directors and we currently have a Nominating and Corporate Governance Committee the members of which are all independent directors. If we were to fully avail ourselves of the controlled company rules, you do not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements.
CKLS controls us and its interests may conflict with ours or yours in the future.
CKLS, through its wholly-owned subsidiary DEFJ, beneficially owns approximately 83.5% of the voting power of our common stock as of August 10, 2026. For so long as CKLS continues to have voting power over a significant percentage of our common stock, even if such amount is less than 50%, it will still be able to significantly influence the composition of our Board and the approval of actions requiring stockholder approval. Although the holders of our common stock will be entitled to vote on all matters on which stockholders of a corporation are generally entitled to vote under the Delaware General Corporation Law (the “DGCL”), including the election of our Board, CKLS’s voting power may effectively allow it to control the outcome of matters submitted to our stockholders for approval. Accordingly, CKLS will have significant influence with respect to our Board, management, business plans and policies, including the appointment and removal of our officers. In particular, for so long as CKLS continues to beneficially own a significant percentage of our common stock, it will be able to cause or prevent a change of control of our company or a change in the composition of our Board and could preclude any unsolicited acquisition of our company. CKLS’s ownership could deprive you of an opportunity to receive a premium for your shares of common stock as part of a sale of our company and ultimately might affect the market price of our common stock.
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a)Unregistered Sales of Equity Securities
None.
(b)Use of Proceeds from Initial Public Offering of Common Stock
Not applicable.
51
Table of Contents
(c)Issuer Purchases of Equity Securities
None.
ITEM 3. Defaults upon Senior Securities
None.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION.
(c) Rule 10b5-1 Trading Arrangements.
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended September 30, 2026, none of the Company’s directors or officers
ITEM 6. Exhibits
3.1 | Amended and Restated Certificate of Incorporation of TransCode Therapeutics, Inc. (Incorporated by reference to Exhibit 3.3 to the Registrant’s Amendment No. 2 to Registration Statement on Form S-1, filed on April 8, 2021 (File No. 333-253599)). | |
| | |
3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of TransCode Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the Registrant’s Form 10-K for the year ended December 31, 2023, filed on April 1, 2024). | |
| | |
3.3 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of TransCode Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on January 16, 2024). | |
| | |
3.4 | | Certificate of Amendment to Amended and Restated Certificate of Incorporation of TransCode Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on November 29, 2024). |
| | |
3.5 | | Certificate of Amendment to Amended and Restated Certificate of Incorporation of TransCode Therapeutics Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on May 5, 2025). |
| | |
3.6 | | Amended and Restated Bylaws of TransCode Therapeutics, Inc. (Incorporated by reference to Exhibit 3.5 to the Registrant’s Amendment No. 2 to Registration Statement on Form S-1, filed on April 8, 2021 (File No. 333-253599)). |
| | |
3.7 | | Amendment No. 1 to the Amended and Restated Bylaws of TransCode Therapeutics, Inc., effective as of December 8, 2023 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on December 8, 2023). |
| | |
3.8 | | Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock of TransCode Therapeutics, Inc., dated July 16, 2026 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on July 17, 2026). |
| | |
3.9 | | Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock of TransCode Therapeutics, Inc., dated August 3, 2026 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on August 3, 2026). |
| | |
4.1 | | Form of Common Warrant (Incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed with the SEC on March 25, 2025). |
| | |
52
Table of Contents
4.2 | | Form of Placement Agent Warrant (Incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed with the SEC on March 25, 2025). |
| | |
4.3 | | Registration Rights Agreement dated October 8, 2025, by and between TransCode Therapeutics, Inc. and DEFJ, LLC (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on October 8, 2025). |
| | |
4.4 | | Form of Convertible Promissory Notes issued to YA II PN, Ltd. (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on April 7, 2026). |
| | |
4.5 | | Registration Rights Agreement, dated as of April 6, 2026, by and between TransCode Therapeutics, Inc. and YA II PN, Ltd. (Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on April 7, 2026). |
| | |
4.6 | | Equity Issuance and Registration Rights Agreement by and between TransCode Therapeutics, Inc. and Unleash Immuno Oncolytics, Inc., dated March 2, 2026 (Incorporated by reference herein from Exhibit 4.22 to the Company’s Annual Report on Form 10-K, filed on April 15, 2026). |
| | |
10.1 | | Standby Equity Purchase Agreement, dated as of April 6, 2026, between TransCode Therapeutics, Inc. and YA II PN, Ltd. (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on April 7, 2026). |
| | |
10.2# | | Amendment No. 3 to the TransCode Therapeutics, Inc. 2021 Stock Option and Incentive Plan (incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement filed on June 2, 2026). |
| | |
10.3# | | Separation and Transition Services Agreement, dated September 9, 2026, between TransCode Therapeutics, Inc. and Thomas A. Fitzgerald (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 11, 2026). |
| | |
31.1* | | Certification of principal executive officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
| | |
31.2* | | Certification of principal financial officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
| | |
32.1** | | Certification of principal executive officer pursuant to Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code. |
| | |
32.2** | | Certification of principal financial officer pursuant to Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code. |
| | |
101.INS* | | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| | |
101.SCH* | | Inline XBRL Taxonomy Extension Schema document. |
| | |
101.CAL* | | Inline XBRL Taxonomy Extension Calculation Linkbase document. |
| | |
101.DEF* | | Inline XBRL Taxonomy Extension Definition Linkbase document. |
| | |
101.LAB* | | Inline XBRL Taxonomy Extension Label Linkbase document. |
| | |
101.PRE* | | Inline XBRL Taxonomy Extension Presentation Linkbase document. |
| | |
104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* | Filed herewith. |
** | These certifications are being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
# | Indicates a management contract or compensatory plan, contract or arrangement |
53
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TRANSCODE THERAPEUTICS, INC. | |
Date: November 16, 2026 | /s/ Philippe P. Calais |
Philippe P. Calais | |
Chief Executive Officer | |
(Principal Executive Officer) |
Date: November 16, 2026 | /s/ John Tattory |
John Tattory | |
Interim Chief Financial Officer | |
(Principal Financial Officer and Principal Accounting Officer) |
54